



Drug Information Update

February 2021

Table of Contents

NEWLY AVAILABLE GENERICS 3
NEW DRUG ENTITIES/STRENGTHS/COMBINATIONS 5
NEW INDICATIONS (EXISTING DRUGS) 7
FDA NEWS/BULLETINS/ADVISORIES/SAFETY ALERTS 9
STUDIES AND RECENT TOPICS 15
RECALLS..... 21
CURRENT DRUG SHORTAGES 31

NEWLY AVAILABLE GENERICS

GENERIC DRUG NAME	STRENGTH AND DOSAGE FORM	GENERIC MANUFACTURER	BRAND NAME
NAPROXEN	750 mg TBMP 24HR	ALVOGEN INC	NAPRELAN
EMTRICITABINE- TENOFIVIR	100 mg-150 mg, 133 mg- 200 mg, 167 mg-250 mg TABLET	AMNEAL	TRUVADA
ZOLMITRIPTAN	2.5 mg, 5 mg SPRAY	AMNEAL	ZOMIG
IMIQUIMOD	3.75 % CREAM PACK	TARO PHARM USA	ZYCLARA
EPOPROSTENOL SODIUM	0.5 mg, 1.5 mg VIAL	SUN PHARMACEUTICAL	VELETRI
FOSCARNET SODIUM	24 mg/mL INFUS. BTL	FRESENIUS KABI	FOSCAVIR

GLUCAGON,HUMAN RECOMBINANT	1 mg VIAL	AMPHASTAR PHARM	GLUCAGON EMERGENCY KIT
CEFAZOLIN SODIUM IN 0.9 % NACL	3 gram/100 mL PIGGYBACK	INTEGRADOSE COM	CEFAZOLIN SODIUM-0.9% NACL
MAGNESIUM SULFATE IN 0.9% NACL	2 gram/50 mL PIGGYBACK	INTEGRADOSE COM	MAGNESIUM SULFATE-0.9% NACL
LOTEPREDNOL ETABONATE	0.5% OPHTHALMIC DROP GEL	AKORN INC	LOTEMAX

NEW DRUG ENTITIES/STRENGTHS/COMBINATIONS

DESCRIPTION	BRAND NAME	GENERIC NAME	STRENGTH	COMMENTS
ANTIPARKINSONISM DRUGS, OTHER	ONGENTYS	OPICAPONE	25 mg CAPSULE	NEW STRENGTH
TOPICAL ANTINEOPLASTIC PREMALIGNANT LESION AGENTS	KLISYRI	TIRBANIBULIN	1 % OINTMENT	NEW ENTITY
ANTI-ARTHRITIC, FOLATE ANTAGONIST AGENTS	REDITREX	METHOTREXATE/ PF	7.5 mg/0.3 mL, 10 mg/0.4 mL, 12.5 mg/0.5 mL, 15 mg/0.6 mL, 17.5 mg/0.7 mL, 20 mg/0.8 mL, 22.5 mg/0.9 mL, 25 mg/mL SC SYRINGE	NEW DOSAGE FORM AND STRENGTH
ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITOR	ICLUSIG	PONATINIB HCL	10 mg, 30 mg TABLET	NEW STRENGTH
URINARY TRACT ANTISPASMODIC, M(3) SELECTIVE ANTAG.	VESICARE LS	SOLIFENACIN SUCCINATE	1 mg/mL ORAL SUSP	NEW DOSAGE FORM AND STRENGTH
PRENATAL VITAMIN PREPARATIONS	DERMACINRX PRENATRIX	PRENATAL VIT NO.170/IRON/FOLIC	27 mg IRON-1 mg TABLET	NEW DOSAGE FORM AND STRENGTH
IMMUNOSUPPRESSIVES	LUPKYNIS	VOCLOSPORIN	7.9 mg CAPSULE	NEW ENTITY
ANTIRETROVIRAL-INTEGRASE INHIBITOR AND NNRTI COMB	CABENUVA	CABOTEGRAVIR/ RILPIVIRINE	400 mg/2 mL-600 mg/2 mL, 600 mg/2 mL-900 mg/2 mL IM VIAL	NEW ENTITY
SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATOR	VERQUVO	VERICIGUAT	2.5 mg, 5 mg, 10 mg TABLET	NEW ENTITY
BILE SALTS	RELTONE	URSODIOL	200 mg, 400 mg CAPSULE	NEW STRENGTH

CYSTIC FIBROSIS - INHALED OSMOTIC AGENTS	BRONCHITOL	MANNITOL	40 mg INHALATION CAP/DEVICE	NEW ROUTE, DOSAGE FORM, AND STRENGTH
ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	TEPMETKO	TEPOTINIB HCL	225 mg TABLET	NEW ENTITY
JANUS KINASE (JAK) INHIBITORS	XELJANZ	TOFACITINIB CITRATE	1 mg/mL ORAL SOLN	NEW STRENGTH
ANTICHOLINERGICS, QUATERNARY AMMONIUM	GLYRX-PF	GLYCOPYRROLATE/PF	1 mg/5 mL (0.2 mg/mL) SYRINGE	NEW DOSAGE FORM AND STRENGTH
ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	UKONIQ	UMBRALISIB TOSYLATE	200 mg TABLET	NEW ENTITY
ANTINEOPLASTIC-CD19 DIR. CAR-T CELL IMMUNOTHERAPY	BREYANZI	LISOCABTAGENE MARALEUCEL	1.5 x 10 ⁶ to 70 x 10 ⁶ cell/mL IV VIAL	NEW ENTITY
KINASE INHIBITOR	COSELA	TRILACICLIB	300 mg IV VIAL	NEW ENTITY
ANTIHYPERLIPIDEMIC - ANGIOPOIETIN-LIKE 3 INHIBITOR	EVKEEZA	EVINACUMAB-DGNB	1,200 mg/8 mL, 345 mg/2.3 mL IV VIAL	NEW ENTITY
ANTIVIRAL MONOCLONAL ANTIBODIES	ETESEVIMAB (EUA)	ETESEVIMAB	700 mg/20 mL (35 mg/mL) IV VIAL	NEW ENTITY (EUA)

NEW INDICATIONS (EXISTING DRUGS)

Opdivo®

January 22, 2021

Bristol Myers Squibb today announced that Opdivo® (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with Cabometyx® (cabozantinib) 40 mg once daily tablets was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The approval is based on the Phase 3 CheckMate -9ER trial, which compared Opdivo® in combination with Cabometyx® (n=323) versus sunitinib (n=328) in patients with advanced RCC. This application was reviewed under the FDA's Real-Time Oncology Review (RTOR) pilot program, which aims to ensure that safe and effective treatments are available to patients as early as possible.

Source: Bristol Myers Squibb

Gocovri®

February 02, 2021

Adamas Pharmaceuticals, a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application for Gocovri® (amantadine) extended release capsules, gaining a second indication for the product. Gocovri® is now approved as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes, in addition to its indication for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Source: Adamas Pharmaceuticals.

Libtayo®

February 05, 2021

The U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HPI) or for whom an HPI is not appropriate. Full approval was granted for patients with locally advanced BCC and accelerated approval was granted for patients with metastatic BCC.

Source: Sanofi

Botox®

February 10, 2021

Allergan, an AbbVie company, today announced that the U.S. Food and Drug Administration (FDA) has approved Botox® for the treatment of detrusor (bladder muscle) overactivity associated with a neurologic condition in



pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.

Source: Allergan, an AbbVie Company

Entresto®

February 16, 2021

Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. The label also states LVEF is a variable measure and clinical judgment should be used in deciding whom to treat.

Source: Novartis.us

FDA NEWS/BULLETINS/ADVISORIES/SAFETY ALERTS

Nostrum Laboratories, Inc. Expands Voluntary Nationwide Recall of Metformin HCl Extended Release Tablets, USP 750 mg, Due to N-Nitrosodimethylamine (NDMA) Content Above the Acceptable Daily Intake (ADI) Limit [Posted 01/25/2021]

Nostrum Laboratories, Inc. is voluntarily recalling one lot of Metformin HCl Extended Release Tablets, USP 750 mg (generic equivalent to Glucophage Tablets) to the consumer level. The Metformin HCl Extended Release Tablets, USP 750 mg (generic equivalent to Glucophage Tablets) have been found to contain levels of nitrosamine impurities above the ADI limit of 96 ng/day, as published in the FDA Guidance Document issued September 2020. This is an expansion of the recall initially announced on November 2nd 2020.

NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables. To date, Nostrum Laboratories, Inc. has not received any reports of adverse events related to this recall.

The product is indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus and is packaged in HDPE bottles of 100 tablets, under NDC 29033-056-01. The affected Metformin HCl Extended Release Tablets, USP 750 mg (generic equivalent to Glucophage Tablets) lot is listed in the table below. The product can be identified as an off-white oblong tablet debossed with “NM7”. distributed nationwide in the USA to wholesalers who further distributed to pharmacies and patients.

Product Description	NDC	Lot Number	Expiry Date
Metformin HCl Extended Release Tablets, USP 750 mg (generic equivalent to Glucophage Tablets)	29033-056-01	MET200601	07/2022

Nostrum Laboratories, Inc. is notifying its distributors by letter and is arranging for return of all recalled products. Pharmacies that have Metformin HCl Extended Release Tablets, USP 750 mg (generic equivalent to Glucophage Tablets) which is being recalled should return to place of purchase. Consumers should consult a healthcare professional to obtain a replacement or a different treatment option. It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their healthcare professional. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking this drug product.



Consumers with medical questions regarding this recall can contact Nostrum Laboratories, Inc. Medical Affairs at phone number 816-308-4941 or email quality@nostrumpharma.com Monday through Friday from 8 am – 5 pm CST. Consumers should contact their physician or pharmacy for further medical advice.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

- Complete and submit the report Online
- Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Source: U.S. Food and Drug Administration (FDA)

Meitheal Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Cisatracurium Besylate Injection, USP 10mg per 5mL Due to Mislabeling

[Posted 01/ 27/ 2021]

Meitheal Pharmaceuticals, Inc. (“Meitheal”), announced today that it is voluntarily recalling one (1) lot of Cisatracurium Besylate Injection, USP 10mg per 5mL to the user level. The decision to recall the product was made after a product complaint revealed that a portion of Lot C11507A of cartons labeled as Cisatracurium Besylate Injection, USP 10mg per 5mL, containing 10-vials per carton, contained 10-vials mis-labeled as Phenylephrine Hydrochloride Injection, USP 100mg per 10mL. To date, Meitheal has not received reports of any adverse events or identifiable safety concerns attributed to the lot.

There is a reasonable probability that a patient who requires cisatracurium for muscle paralysis as part of general anesthesia is administered phenylephrine instead would not receive any skeletal muscle relaxation and could cause a hyperadrenergic state resolution in elevated blood pressure, arrhythmia and cardiac/brain ischemia. If this is not quickly diagnosed and treated, severe illness or death can occur.

There is a reasonable probability that a patient who requires phenylephrine to increase their blood pressure, such as patients with severely low blood pressure, especially resulting from septic shock who is administered cisatracurium instead could result in a fast onset of muscle paralysis and decrease in oxygen. If this is not quickly diagnosed and treated, severe illness or death can occur within minutes.

Cisatracurium Besylate Injection is used as a nondepolarizing neuromuscular blocker. The affected Cisatracurium Besylate Injection lot being recalled is C11507A, EXP. October 2021. The product can be identified as a 5mL vial stoppered with a rubber stopper and sealed with aluminum seal having an Aqua color flip-off seal. Meitheal commenced shipping the product to customers on August 19, 2020 which was distributed to wholesalers nationwide in the USA.

Product	Lot Number	Expiration Date	NDC Number	Distribution Dates
Cisatracurium Besylate Injection, USP 10 mg per 5 mL	C1157A*	October 2021*	71288-712-06 (unit of sale) 71288-712-05 (unit of sale)	August 19, 2020 – January 04, 2021

*Note: Mis-labeled product will have this same Lot Number of C11507A and Expiration Date of October 2021 but will be labeled on the vial as Phenylephrine Hydrochloride Injection, USP 100mg per 10mL, NDC 71288-808-77 (unit of use).

Meitheal has notified its distributors and customers in writing to arrange for return of all recalled product. Customers who have purchased the product should not open the carton or use its contents and should immediately quarantine and return the recalled lot of product. Customers who may have further distributed this product should promptly identify their customers and notify them at once of this product recall.

Consumers with questions regarding this recall can contact Meitheal’s Customer Service weekdays 8:00AM to 6:00PM CST at 844-824-8426. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax, as follows.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

- Complete and submit the report Online
- Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Source: U.S. Food and Drug Administration (FDA)

[Apotex Corp. Issues Voluntary Nationwide Recall of Enoxaparin Sodium Injection, USP Due to Mislabeling of Syringe Barrel Measurement Markings](#)

[Posted 02/03/2021]

Apotex Corp is voluntarily recalling two (2) batches of Enoxaparin Sodium Injection, USP to consumer level due to a packaging error resulting in some syringes barrels containing 150 mg/mL markings (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL strength) on the syringe barrel and vice versa. The packaging error was discovered during a customer complaint investigation. To date, Apotex has not received any reports of adverse events related to use of these two batches. The affected product is manufactured by Gland Pharma Limited, Hyderabad, India.

Health Hazard Assessment: Incorrect syringe barrel marking could lead to miscalculation and inaccurate dose administration to patients. In one recalled batch (batch CS008, strength 100 mg/mL), if a consumer used a 150 mg/mL concentration packaged in a barrel corresponding to a 100 mg/mL concentration.

Enoxaparin Sodium injection is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), Treatment of Acute Deep Vein Thrombosis, prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin and Treatment of Acute ST-Segment Elevation Myocardial Infarction.

The affected Enoxaparin Sodium Injection, USP can be identified by NDC numbers stated on carton and label of the product.

Product	Batch #	Strength	Syringe Barrel Measurement Marking	Pack Size	NDC # on Carton	NDC # on Label	UPC Code on Carton	UPC Code on Label
Enoxaparin Sodium Injection, USP	C5008	100 mg/mL	100 mg/mL	10 x 1 mL Single Dose Syringes	60505-0795-4	60505-0795-1	360505079544	(01)10360505079510
	CT003	150 mg/mL	100 mg/mL	10 x 0.8 mL Single Dose Syringe	60505-0796-0	60505-0796-0	360505079643	(01)10360505079602

The two (2) affected batches of Enoxaparin Sodium Injection, USP were distributed by Apotex nationwide in the USA to Wholesalers and Warehousing Chains. Apotex Corp. is currently notifying its affected direct account Wholesalers and Warehousing Chains, via mail (FedEx Standard Overnight) by mailing a recall notification letter and is arranging for return of all recalled product.

Patients who have received either of the two (2) impacted batches of Enoxaparin Sodium Injection, USP or have questions regarding this recall should contact their pharmacy. Individuals should not interrupt their therapy, should immediately contact their health care provider for medical advice and should return the impacted product to Inmar Rx Solutions by contacting at the numbers provided in this press release.



Wholesalers, Distributors and Retailers should return the recalled product to the place of purchase. Anyone with an existing inventory of the product should quarantine the recalled batches immediately. Customers who purchased the impacted product directly from Apotex can call Inmar Rx Solutions at 1-855-667-8717 (9:00am – 5:00-pm, EST Monday thru Friday), to arrange for their return.

Consumers with the affected units of Enoxaparin Sodium Injection, USP, please contact Inmar Rx Solutions (“Inmar”) at 1-855-667-8717, to receive a recall/return packet including the Recall Stock Response Form, or you may obtain this form from clsnetlink.com External Link Disclaimer.

Consumers with questions regarding this recall can contact Apotex Corp. by phone at 1-800-706-5575 (8:30am – 5:00pm, EST Monday thru Friday) or email address UScustomerservice@Apotex.com. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

- Complete and submit the report Online
- Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Source: U.S. Food and Drug Administration (FDA)

[Xeljanz, Xeljanz XR \(tofacitinib\): Drug Safety Communication - Initial Safety Trial Results Find Increased Risk of Serious Heart-related Problems and Cancer with Arthritis and Ulcerative Colitis Medicine.](#)

[Posted 02/04/2021]

ISSUE: The FDA is alerting the public that preliminary results from a safety clinical trial show an increased risk of serious heart-related problems and cancer with the arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib) compared to another type of medicine called tumor necrosis factor (TNF) inhibitors. FDA required the safety trial, which also investigated other potential risks including blood clots in the lungs and death. Those final results are not yet available.

In February 2019 and July 2019, FDA warned that interim trial results showed an increased risk of blood clots and death with the higher 10 mg twice daily dosage, and as a result, approved a Boxed Warning to the tofacitinib prescribing information. The clinical trial is now complete and initial results show a higher occurrence of serious heart-related events and cancer in rheumatoid arthritis (RA) patients treated with both doses of tofacitinib compared to patients treated with a TNF inhibitor. FDA is awaiting additional results from the trial.

BACKGROUND: Tofacitinib was approved in 2012 to treat adults with RA who did not respond well to the medicine methotrexate. In 2017, FDA approved tofacitinib to treat patients with a second condition that causes joint pain and swelling, psoriatic arthritis (PsA), who did not respond well to methotrexate or other similar medicines. In 2018, FDA approved the medicine to treat ulcerative colitis, which is a chronic, inflammatory



disease affecting the colon. Tofacitinib works by decreasing the activity of the immune system; an overactive immune system contributes to RA, PsA, and ulcerative colitis.

RECOMMENDATION: Patients should not stop taking tofacitinib without first consulting with your health care professionals, as doing so may worsen your condition. Talk to your health care professionals if you have any questions or concerns.

Health care professionals should consider the benefits and risks of tofacitinib when deciding whether to prescribe or continue patients on the medicine. Continue to follow the recommendations in the tofacitinib prescribing information.

Health professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

- Complete and submit the report Online
- Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Source: U.S. Food and Drug Administration (FDA)

STUDIES AND RECENT TOPICS

[Aspirin and CRC Risk: A Curious Age Connection](#)

January 21, 2021

Regular aspirin use at or after age 70 was associated with significantly reduced risk of colorectal cancer (CRC), but only in those who were already taking aspirin before turning 70, according to pooled data from two large cohorts of U.S. health professionals.

Source: medpagetoday.com

[Impact of Antidepressants Examined in Back Pain, Osteoarthritis](#)

January 21, 2021

Serotonin-noradrenaline reuptake inhibitors (SNRIs) have a small and not clinically important effect on back pain, but may have a clinically important effect for osteoarthritis, according to a review published online Jan. 20 in The BMJ.

Source: healthday.com

[Drug Prices: We've Seen This Movie Before](#)

January 22, 2021

Before 1973, when the Arab oil embargo upended the U.S. auto industry, Americans witnessed an annual ritual by carmakers. In the late summer, the Big Three -- Ford, Chrysler, and General Motors -- would release sticker prices for their products, always showing increases, of course.

Source: medpagetoday.com

[Anaphylaxis Cases with Moderna COVID-19 Vax Follow Similar Pattern](#)

January 22, 2021

Ten cases of anaphylaxis and over 100 cases of severe allergic reactions were reported following administration of the first dose of the Moderna COVID-19 vaccine, but nearly all were among those with a history of allergic reactions, researchers found.

Source: medpagetoday.com

[Pfizer ships fewer Covid vaccine vials to U.S. after Trump FDA label change](#)

January 22, 2021

Pfizer is counting extra coronavirus vaccine it uses to top off each of its vials toward its commitment to deliver 200 million shots for the U.S. pandemic response — even though there aren't enough syringes capable of squeezing out the extra fluid.

Source: politico.com

UK study shows azithromycin, doxycycline ineffective in early COVID-19

January 25, 2021

A British study found widely used antibiotics azithromycin and doxycycline were generally ineffective against early-stage COVID-19, as the search for treatments against the illness continues while vaccines are being rolled-out. Source: reuters.com

Exclusive: Scarce niche syringes complicate U.S. plan to squeeze more COVID shots from Pfizer vials

January 25, 2021

The U.S. government's effort to squeeze more doses from Pfizer Inc's COVID-19 vaccine vials is spurring unanticipated demand for specialized syringes that the world's largest syringe supplier says exceeds existing capacity. Source: reuters.com

Moderna says it believes vaccine will work against new variants

January 25, 2021

Moderna Inc said on Monday it believes its COVID-19 vaccine protects against new variants found in Britain and South Africa, although it will test a new booster shot aimed at the South African variant after concluding the antibody response could be diminished.

Source: reuters.com

WHO revises guidance for COVID-19 patients' treatment, recommending follow-up care, low-dose anticoagulants

January 26, 2021

The World Health Organization (WHO) on Tuesday issued new guidance for treatment of coronavirus patients, including those with persistent post-recovery symptoms.

The advice includes the use of at-home oxygen saturation testing for those who have been discharged from hospitals and low-dose anticoagulants for patients who remain hospitalized to prevent thrombosis.

Source: thehill.com

Johnson & Johnson on track for 100 million vaccine doses by end of June, bolstering US supply

January 26, 2021

Johnson & Johnson said Tuesday that it is on track to meet its target of 100 million coronavirus vaccine doses for the United States by the end of June, one of a string of confident announcements on vaccine supply.

Source: thehill.com

New drug may be potent against the coronavirus

January 26, 2021

The chemical compound plitidepsin (trademarked name Aplidin) was first extracted from a sea organism known as Aplidium albicans, commonly known as sea squirts. Researchers recently published in Science the results of preclinical experiments involving using plitidepsin to treat human and mouse cells infected with SARS-CoV-2. They found evidence that suggests it's possible this drug can be used as a therapy for COVID-19.

Source: thehill.com

High Potassium No Threat with Spironolactone

January 27, 2021

Some prescribers of spironolactone (CaroSpir, Aldactone) for acne are still monitoring patients' potassium levels despite the move to eliminate this practice, a new study found.

In a retrospective cohort study of over 100,000 female patients with acne, the percentage of healthcare providers who measured potassium levels within 180 days of starting spironolactone dropped from 41.4% in 2008 to 38.5% in 2018, reported John Barbieri, MD, MBA, of the University of Pennsylvania in Philadelphia, and colleagues. Source: medpagetoday.com

Diabetes Etiology Varies by Race/Ethnicity

January 27, 2021

Ethnic differences emerged among subgroups of diabetes characteristics, a new study found.

In an analysis of nearly 1,300 people with diabetes, five distinct types of diabetes cases were identified -- older age at diabetes onset (43%), severe hyperglycemia (26%), severe obesity (20%), younger age at onset (1%), and requiring insulin medication use (9%), reported Michael Bancks, PhD, MPH, of Wake Forest School of Medicine in Winston-Salem, North Carolina, and colleagues.

Source: medpagetoday.com

Pfizer vaccine only slightly less effective against key South African mutations – study

January 27, 2021

Pfizer Inc and BioNTech's COVID-19 vaccine appeared to lose only a small bit of effectiveness against an engineered virus with three key mutations from the new coronavirus variant found in South Africa, according to a laboratory study conducted by the U.S. drugmaker.

Source: reuters.com

Here's How Much More the U.S. Spends on Rx Drugs

January 28, 2021

The U.S. spent about 150% more on prescription drugs in 2018 compared with dozens of other countries, according to a new RAND Corporation analysis.

On average, prescription drug prices were 2.56 times higher in the U.S. than in 32 other Organization for Economic Cooperation and Development (OECD) member nations, reported RAND's Andrew Mulcahy, PhD, MPP, and colleagues.

Source: medpagetoday.com

Pandemic spurs quest to enroll more Black Americans in vaccine trials

January 28, 2021

Branche and colleagues at the University of Rochester Medical Center in New York were running a clinical trial for a vaccine against the coronavirus, which kills Black people at three times the rate it kills whites - yet it was mostly whites signing up. They needed more African Americans.

Source: reuters.com

Teens Commonly Misuse Their Prescribed Psych Meds

February 2, 2021

More than one-fifth of American youth reported misuse of their psychoactive prescription, a new study found. In a survey of kids ages 12-17 prescribed opioids, stimulants, tranquilizers, or sedatives, 20.9% -- equating to about 1.3 million youth -- said they used their medication in a way that wasn't prescribed or directed for them within the previous year, reported Israel Agaku, PhD, of Harvard School of Dental Medicine in Boston, and colleagues.

Source: medpagetoday.com

Brain Tumor Risk Upped With Synthetic Progestogen

February 3, 2021

Women taking the synthetic progestogen cyproterone acetate were at increased risk for brain tumors, a French study found. The analysis of data on over 250,000 girls and women who filled a prescription for cyproterone acetate showed that these individuals had a six-fold higher risk for developing an intracranial meningiomas compared with women not using the hormone (adjusted hazard ratio 6.6, 95% CI 4.0-11.1), reported Alain Weill, MD, of EPI-PHARE Scientific Interest Group in France, and colleagues in The BMJ.

Source: medpagetoday.com

Exclusive: Merck anti-baldness drug Propecia has long trail of suicide reports, records show

February 3, 2021

Newly unsealed court documents and other records show that Merck & Co and U.S. regulators knew about reports of suicidal behavior in men taking the company's anti-baldness treatment Propecia when they decided not to warn consumers of those potential risks in a 2011 update of the popular drug's label.

Source: reuters.com

Abrupt Cessation of Long-Term Opioid Prescribing Common

February 4, 2021

Medicare beneficiaries were increasingly likely to have long-term opioid therapy stopped in recent years and medication changes often were abrupt, not tapered, an observational study showed.

Source: medpagetoday.com

U.S. FDA gearing up for rapid review of potential COVID-19 booster shots

February 4, 2021

The U.S. Food and Drug Administration is planning a rapid review process for quick turnaround of new COVID-19 booster shots if variants of the coronavirus emerge against which the vaccines do not provide protection, the agency's top official said on Thursday.

Source: reuters.com

FDA OKs Expanded Use of Peramivir Injection in Younger Patients with Influenza

February 4, 2021

Peramivir injection is indicated for the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 2 days. It is administered via an intravenous (IV) infusion for a minimum of 15 minutes at recommended doses of 600 mg/kg for adults and adolescents and 12 mg/kg for pediatric patients aged 6 months to 12 years.

Source: drugtopics.com

White House to Boost At-Home COVID Tests, Vaccine Deliveries

February 5, 2021

Tens of millions at-home coronavirus tests will be available by the end of the summer, the White House's COVID-19 Response Team said during a press briefing on Friday.

"At-home tests are one of the key steps to getting back to normal life," said Andy Slavitt, a senior advisor to the White House's COVID-19 Response Team.

Source: medpagetoday.com

FDA warns Pfizer's arthritis, colitis drug raises risk of heart issues and cancer

February 5, 2021

The Food and Drug Administration (FDA) on Thursday warned that early results from a safety trial on Pfizer's arthritis and colitis drug, tofacitinib, revealed an increased risk of heart issues and cancer when compared to another medicine.

Source: foxnews.com

[HDL Cholesterol Linked to Parkinson's Disease](#)

February 5, 2021

Lower levels of high-density lipoprotein cholesterol (HDL-C) and greater HDL-C variability were linked to higher incidence of Parkinson's disease, a population-based longitudinal study in Korea showed.

Source: medpagetoday.com

[COVID-19 tests can spot variants, lab companies insist](#)

February 9, 2021

As public health officials warn that the new COVID-19 variant originating in the U.K. could become dominant across the U.S. by March, the nation's largest testing companies and laboratories say their coronavirus tests are prepared to accurately identify new virus strains as they emerge.

Source: abcnews.go.com

[Get ready for Covid-19 vaccine booster shots at your next physical, experts warn](#)

February 10, 2021

Will your yearly physical include a Covid-19 vaccine booster shot? Probably, experts said Wednesday. The coronavirus has shown it can mutate like the flu and the vaccines will have to be updated to counter new strains, they said.

Source: nbcnews.com

[Semaglutide Shines as Weight Loss Therapy](#)

February 10, 2021

In conjunction with lifestyle management, once-weekly semaglutide helped people with obesity lose a significant amount of weight, the Semaglutide Treatment Effect in People with Obesity (STEP) 1 study found.

Source: medpagetoday.com

[COVID-19 Vax Joins List of 2021 Recommended Vaccines](#)

February 11, 2021

Vaccination against COVID-19 during the pandemic was officially added to the 2021 adult and child immunization schedule, according to updated immunization guidelines released on Thursday. In December, the CDC's Advisory Committee on Immunization Practices (ACIP) recommended any COVID-19 vaccine authorized under the scope of use of an FDA emergency use authorization during the pandemic.

Source: medpagetoday.com

RECALLS

Product Type	Product Description	Classification	Code Info	Reason For Recall	Recalling Firm
Drugs	Ketorolac Tromethamine Injection, USP, 30 mg per mL, packaged in 1 mL Single Dose Vials (NDC 63323-162-00); 25 x 1 mL Single Dose Vials per tray (NDC 63323-162-01); For IM or IV use, Rx only, Fresenius Kabi, Lake Zurich, IL 60047.	Class I	Lot # 6121083, Exp 2/2021	Presence of Particulate Matter - found in reserve sample vials at the firm.	Fresenius Kabi USA, LLC
Drugs	Enoxaparin Sodium Injection, USP 100 mg/mL Single Dose Syringes with Automatic Safety Device For Subcutaneous Injection 10 x 1 mL Single Dose Syringes Rx Only, Manufactured by: Gland Pharma Ltd. Hyderabad, India Manufactured for: Apotex Corp. Weston, FL 33326 NDC 60505-0795-4 UPC 360505079544 (carton) NDC 60505-0795-1 UPC (01)10360505079510 (label)	Class I	Batch: CS008 Exp. 04/2022	Labeling; Label Mixup; syringe barrels may contain markings for 150 mg/mL (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL strength)	Apotex Corp.
Drugs	Enoxaparin Sodium Injection, USP 120 mg/ 0.8 mL Single Dose Syringes with Automatic Safety Device For Subcutaneous Injection 10 x 0.8 mL Single Dose Syringes Rx Only, Manufactured by: Gland Pharma Ltd. Hyderabad, India Manufactured for:	Class I	Batch: CT003 Exp. 05/2022	Labeling; Label Mixup; syringe barrels may contain markings for 100 mg/mL (corresponding to 100 mg/mL strength) instead of 150 mg/mL (corresponding to 120 mg/0.8mL strength)	Apotex Corp.

	Apotex Corp. Weston, FL 33326 NDC 60505-0796-4 UPC 360505079543 (carton) NDC 60505-0796-0 UPC (01)10360505079602 (label)				
Drugs	OPTIMUS LUBRICANTS Instant Hand Sanitizer, (ethyl alcohol 70%) 8.5 Fl. Oz. (250 mL) bottle, Made in Mexico, Liq-E, S.A. DE C.V., Puerto Tampico No. 345 Col. La Fe San Nicolas de Los Garza, Nuevo Leon, Mexico. C.P. 66477. UPC # 7 501799 115621	Class I	Lot # (L)20-02, exp. date 05/2022	Chemical Contamination: Products contain methanol and were below the label claim for ethanol content	Liq-E S.A. De C.V.
Drugs	OPTIMUS LUBRICANTS Instant Hand Sanitizer, (alcohol 70% v/v) 55 Gal (208 L) drum, Made in Mexico, Liq-E, S.A. DE C.V., Puerto Tampico No. 345 Col.. La Fe San Nicolas de Los Garza, Nuevo Leon, Mexico. C.P. 66477.UPC # 7 501799 118998	Class I	Lot # L-1160, L-2160, L-3160, L-1180, L-2180, L-2190, Exp. 05/2022 ; L-1200, L-2200, L-3200, L-4200, L-5200, L-1210 and L-2210, Exp. date 06/2022	Chemical Contamination: Products contain methanol and were below the label claim for ethanol content	Liq-E S.A. De C.V.
Drugs	OPTIMUS LUBRICANTS Instant Hand Sanitizer, (ethyl alcohol 70%) 1 Gal (3.78 L) bottle, Made in Mexico, Liq-E, S.A. DE C.V., Puerto Tampico No. 345 Col. La Fe San Nicolas de Los Garza, Nuevo Leon,	Class I	Lot # (L) 20-03, exp. date 05/22	Chemical Contamination: Products contain methanol and were below the label claim for ethanol content	Liq-E S.A. De C.V.

	Mexico. C.P. 66477; NDC: XXXXX-378-04, UPC # 7 501799 118837				
Drugs	OPTIMUS LUBRICANTS Instant Hand Sanitizer, (alcohol 70% v/v) 275 Gal (1040 L) tank with spout dispenser, Made in Mexico, Liq-E, S.A. DE C.V., Puerto Tampico No. 345 Col. La Fe San Nicolas de Los Garza, Nuevo Leon, Mexico. C.P. 66477.; UPC # 7 501799 118981	Class I	Lot # (L) 5200, exp. date 05/2022	Chemical Contamination: Products contain methanol and were below the label claim for ethanol content	Liq-E S.A. De C.V.
Drugs	Refresh Relieva PF Preservative-Free Lubricant Eye Drops 0.33 fl oz (10 mL) Sterile Distributed by: Allergan, an AbbVie company Madison, NJ 07940 UPC 3 00236 63410 0, NDC 0023-6634-10.	Class II	Lots: T0392 Exp. Jul. 2022, T0843 Exp. Aug. 2022	Labeling: Missing instructions for use insert	Allergan, PLC.
Drugs	HUMAN CHORIONIC GONADOTROPIN 11,000 IU per vial Aso contains Mannitol 9%, Sodium Phosphate 2% in water for injection. Lyophilized, Unpreserved. Complete Pharmacy & Medical Solutions 5829 NW 158th St, Miami Lakes, FL 33014 Tel: 305-397- 2035	Class II	Lot #: 40568 Use By Date: 01/30/2 021	CGMP deviations: Lack of potency testing.	Complete Pharmacy and Medical Solutions, LLC.
Drugs	HUMAN CHORIONIC GONADOTROPIN 6,000 IU per vial Aso contains Mannitol 9%, Sodium Phosphate 2% in water for injection. Lyophilized, Unpreserved. Complete Pharmacy & Medical Solutions 5829 NW 158th St, Miami Lakes,	Class II	Lot# 40604 Use By date, 01/30/2 021	CGMP deviations: Lack of potency testing.	Complete Pharmacy and Medical Solutions, LLC.

	FL 33014 Tel: 305-397-2035				
Drugs	HUMAN CHORIONIC GONADOTROPIN 5,000 IU per vial Aso contains Mannitol 9%, Sodium Phosphate 2% in water for injection. Lyophilized, Unpreserved. Complete Pharmacy & Medical Solutions 5829 NW 158th St, Miami Lakes, FL 33014 Tel: 305-397-2035	Class II	Lot #: 40570 Use By Date 01/30/2021	CGMP deviations: Lack of potency testing.	Complete Pharmacy and Medical Solutions, LLC.
Drugs	HUMAN CHORIONIC GONADOTROPIN 1,250 IU per vial Aso contains Mannitol 9%, Sodium Phosphate 2% in water for injection. Lyophilized, Unpreserved. Complete Pharmacy & Medical Solutions 5829 NW 158th St, Miami Lakes, FL 33014 Tel: 305-397-2035	Class II	Lot #: 40548, Use By Date, 01/30/2021.	CGMP deviations: Lack of potency testing.	Complete Pharmacy and Medical Solutions, LLC.
Drugs	Ceftazidime Sterile Ophthalmic Solution for Injection Preservative Free 11.25mg / 0.5ml (22.5mg/ml) 0.5ml per syringe. KEEP FROZEN UNTIL USE AND PROTECT FROM LIGHT SINGLE USE SYRINGE FOR INTRAOCULAR INJECTION Edge Pharma, LLC is an FDA-registered 503B outsourcing facility. This is a compounded (re-packaged) drug. Not for Resale, Hospital/Office use only. Edge Pharma, LLC 856 Hercules Dr. Colchester, VT 05446	Class II	Lot # 02-2020-04@4	Lack of Assurance of Sterility; the media used to conduct post-compounding sterility testing for the Methotrexate product was expired.	Edge Pharma, LLC

	Customer Service (USA) 1-802-992-1178				
Drugs	Nitrofurantoin Capsules USP (Monohydrate/Macrocrystals), 100 mg, 100 per carton (10 capsules x 10 blister cards), Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43217, NDC Carton: 68084-446-01; NDC Blister Card: 68084- 446-11	Class II	Lot # 193757, Exp 1/31/2022	Failed Dissolution Specifications	American Health Packaging
Drugs	IMC Wash-Free Hand Sanitizer, (ethyl alcohol), 75%, 1.7 fl. oz. (50 ml) bottles, Distributed by IMC 4284 Shoreline Dr, Spring Park, MN 55384, Made in China, ALSO distributed with Custom front labels as follows a) Sadie G. Mays Health & Rehabilitation Center, b) Pacers logo, c) northwood CHURCH, d) ROGETHEROOFER.com and e) SoFi Stadium Wash-Free Hand Sanitizer. UPC 8 19845 00597 8	Class II	Lot 2020/05/11, exp 2023/05/10	CGMP Deviations: product manufactured at the same facility that produced product that FDA sampled and found to be subpotent for ethanol and contained methanol.	Shane Erickson Inc
Drugs	IMC Wash-Free Hand Sanitizer, (ethyl alcohol), 75%, 3.4 fl. oz. (100 ml), Made in China, Distributed by IMC 4284 Shoreline Dr, Spring Park, MN 55384. Labeled as a) SAFE-GUARD Products International, b) Safe-WAY JEVCO Wash-Free Hand Sanitizer, c) TRACTION CAPITAL, d) United States Census	Class II	Lot: MFG: 2020/05/10 L/N: 202005 10-3	CGMP Deviations: product manufactured at the same facility that produced product that FDA sampled and found to be subpotent for ethanol and contained methanol.	Shane Erickson Inc

	2020. UPC 8 19845 00598 5				
Drugs	IMC Wash-Free Hand Sanitizer, (ethyl alcohol), 75%, 10.1 fl. oz. (300 ml), Made in China, Distributed by IMC 4284 Shoreline Dr, Spring Park, MN 55384. Labeled as Thrifty White Pharmacy Wash-Free Hand Sanitizer. UPC 8 19845 00599 2	Class II	Lot: 2020/05 /11, exp 2023/05 /10	CGMP Deviations: product manufactured at the same facility that produced product that FDA sampled and found to be subpotent for ethanol and contained methanol.	Shane Erickson Inc
Drugs	Acetaminophen Injection 1,000 mg per 100 mL (10 mg/mL), 100 mL Single Dose Vial, For Intravenous Use Only, Distributed by: AuroMedics Pharma LLC 279 Princeton-Hightstown Rd. E. Windsor, NJ 08520 Made in India NDC 55150-307-01	Class II	CAT200 002 exp 9/2022; CAT200 004 exp 9/2022; CAT200 005 exp 9/2022; CAT200 008 exp 9/2022; CAT200 009 exp 9/2022; CAT200 013 exp 10/2022 ; CAT200 014 exp 10/2022 ; CAT200 015 exp 10/2022 ; CAT200 016 exp 10/2022 ; CAT200 017 exp 10/2022 ;	Discoloration and failed pH specifications	AuroMedics Pharma LLC

			CAT200 018 exp 10/2022		
Drugs	Nortriptyline HCl Capsules, USP equivalent to 10mg base Mfd. by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 2624761 Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532 NDC 51672-4001-1	Class II	AC0509 6, AC0509 8, and AC0509 9; Exp 10/31/2022	CGMP deviations.	Taro Pharmaceuticals U.S.A., Inc.
Drugs	Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg, 100 Tablets per bottle, Rx Only, Manufactured by: Nostrum Laboratories, Inc., Kansas City, MO 64120. NDC: 29033-056-01	Class II	Lot MET200 601, 07/2022	CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level.	Nostrum Laboratories Inc
Drugs	Lidocaine/Tetracaine (LIPO110)* 23%/7% Ointment 100 GMS per 4 ounce plastic ointment jar, Rx Only, Stanley Specialty Pharmacy 3120 Latrobe Dr. Suite 200 Charlotte, NC 28211	Class II	Lot: 195789 Exp. Apr. 17 2021	Superpotent Drug. Lidocaine higher concentration than listed	Stanley Specialty Pharmacy Compounding and Wellness Center
Drugs	Cephalexin for Oral Suspension, USP 250 mg per 5 mL, 100 ml (when mixed) Rx Only, Manufactured by: Alkem Laboratories, Ltd, Mumbai -400 013 INDIA Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-545-88	Class II	Lot # 191448 41, Exp 9/2021; 201416 73 Exp 4/2022.	CGMP Deviations: Individual Unidentified impurities results of the product was found at higher side of the specification limit.	Ascend Laboratories LLC

Drugs	Cephalexin for Oral Suspension, USP 250 mg per 5 mL 200 mL (when mixed) Rx Only, Manufactured by: Alkem Laboratories, Ltd, Mumbai -400 013 INDIA Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-545-68	Class II	Lot #: 191418 69, 191418 70, EXP 3/2021; 191427 62, EXP 5/2021; 191438 26, 191439 23,1914 3941, 191439 54 EXP 7/2021	CGMP Deviations: Individual Unidentified impurities results of the product was found at higher side of the specification limit.	Ascend Laboratories LLC
Drugs	Sulfur Ointment 10%, Pomada de Azufre, 2.6 OZ (73.7g) jar; Manufactured by/ Fabricado por: De La Cruz Products, A Division of DLC Laboratories, Inc. Paramount, CA 9023 USA; UPC 024286150426	Class II	Lot # 5084, Exp 05/23; 5130, Exp 07/23; 5132, Exp 07/23; 5160, Exp 08/23.	Labeling: Label Mix-Up. The English label with Drug Facts panel for Camphor was incorrectly placed on product.	DLC Laboratories, Inc
Drugs	Meclizine HCl Tablets, USP, 12.5 mg, 100 Tablets bottles, Rx Only, Mfd. for: Wilshire Pharmaceuticals, Inc., Atlanta, GA 30328, Product of India, NDC 52536-129-01	Class II	Lot #: 180303 18, Exp 03/2021	Failed Dissolution Specifications	Wilshire Pharmaceuticals Inc
Drugs	Meclizine HCl Tablets, USP, 25 mg, 100 Tablets bottles, Rx Only, Mfd. for: Wilshire Pharmaceuticals, Inc., Atlanta, GA 30328, Product of India, NDC 52536-133-01	Class II	Lot #: 180303 29, 180303 30, 180303 31, Exp 03/2021	Failed Dissolution Specifications	Wilshire Pharmaceuticals Inc

Drugs	Mephyton (phytonadione) Tablets 5mg, 100-count bottle, Rx Only, Manufactured for: Valeant Pharmaceuticals North America, LLC Bridgewater, NJ 08807 USA NDC 0187-1704-05	Class III	Lot: 18L092 P, Exp 05/2021	Failed Impurities/Degradation on Specifications: Out of specification during the 24 month stability testing of Impurity D.	Bausch Health Companies, Inc.
Drugs	Phytonadione Tablets 5mg, 30-count bottle, Rx Only, Manufactured For: Oceanside Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC Bridgewater, NJ 08807 USA NDC 68682-170-30	Class III	Lot: 18L091 P, Exp 05/2021	Failed Impurities/Degradation on Specifications: Out of specification during the 24 month stability testing of Impurity D.	Bausch Health Companies, Inc.
Drugs	Testosterone Cypionate Injection, USP CIII 200mg/ml FOR INTRAMUSCULAR USE ONLY 1mL Single-dose vial Distributed by: Sun Pharma Ind. Inc, NJ 08512 Manufactured by: Sun Pharma Ind. Ltd., India NDC 62756-015-40	Class III	Lot JKX2553 A	Incorrect Labeling: Incorrect lot number on secondary packaging	SUN PHARMACEUTICAL INDUSTRIES INC
Drugs	Oseltamivir Phosphate for Oral Suspension, 6 mg/mL, 60 mL (usable volume after constitution), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, Manufactured by: Lupin Limited Aurangabad, Maharashtra, India. NDC: 68180-678-01	Class III	Lot # A906423, exp. date Nov 2021.	Failed Impurities/Degradation on Specifications; Out-of-specification test results observed for Impurity C at 9 month long-term stability time point.	Lupin Pharmaceuticals Inc.
Drugs	Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for:	Class III	Lot: M20136 45 Exp. Aug. 2022	Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister	Accord Healthcare, Inc.

	Accord Healthcare, Inc. Durham, NC 27703, USA. Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad- 382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)			strips labeled for 1 mL vials	
Drugs	Pantoprazole Sodium for Injection 40mg/vial For I.V. infusion only Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 Manufactured by: Sun Pharmaceutical Industries Ltd. Halol- Baroda Highway, Halol- 389 350, Gujarat, India NDC 62756-129-40	Class III	JKU359 5A, JKU359 6A, JKU359 7A, and JKU362 9A; Exp 02/2021	Failed Impurity/Degradatio n Specifications	SUN PHARMACEUTI CAL INDUSTRIES INC
Drugs	Auryxia (ferric citrate) tablets, 210 mg*, 200 tablets bottle, RX ONLY, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., 245 First Street, Suite 1400, Cambridge, MA 02142, USA, NDC 59922-0631-01.	Class III	Lots #: CDKSN, CDPPH, Exp January 2022; Lot #: CDPPK, Exp Februar y 2022.	Failed Dissolution Specifications	Akebia Therapeutics dba Keryx Biopharmaceuti als, Inc

*Please refer to FDA website for further information at: <http://www.fda.gov/Safety/Recalls/default.htm>

CURRENT DRUG SHORTAGES

Tropicamide 1% Ophthalmic Solution

January 21, 2021

Reason for the Shortage

- Akorn has tropicamide 1% ophthalmic drops available.
- Alcon has Mydracyl available.
- Bausch Health did not provide a reason for the shortage.
- Sandoz did not provide a reason for the shortage of tropicamide 1% ophthalmic drops.

Estimated Resupply Dates

- Bausch Health has 1% tropicamide 2 mL bottles on back order and the company estimates a release date of early-April 2021.
- Sandoz has short-dated 1% tropicamide 3 mL bottles available with an expiration date of < October 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=547>

Simethicone Oral Liquid

January 21, 2021

Reason for the Shortage

- Geri-Care did not provide a reason for the shortage.
- GSK Consumer Healthcare discontinued Baby Gas-X simethicone oral solution.
- Major did not provide a reason for the shortage.
- Perrigo discontinued simethicone oral liquid due to low demand for the product.
- Rugby has simethicone oral liquid available.

Estimated Resupply Dates

- Geri-Care has simethicone 20 mg/0.3 mL oral suspension in 30 mL bottles on back order and the company cannot estimate a release date.
- Major has simethicone 20 mg/0.3 mL oral suspension in 30 mL bottles on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=632>

Verapamil Extended-Release Tablets

January 22, 2021

Reason for the Shortage

- Glenmark did not provide a reason for the shortage.
- Mylan did not provide a reason for the shortage.
- Pfizer has Calan SR tablets on shortage due to manufacturing delay.

Estimated Resupply Dates

- Glenmark has all verapamil extended-release tablets on allocation.

- Mylan has verapamil extended-release tablets on back order and the company cannot estimate a release date.
- Pfizer has Calan SR 180 mg tablets on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=555>

Lidocaine Injection

January 22, 2021

Reason for the Shortage

- Amphastar had lidocaine 2% emergency syringes available.
- AuroMedics introduced lidocaine injection in February 2014.
- Fresenius Kabi had generic lidocaine presentations on shortage due to a supply interruption of raw ingredients.
- Pfizer has lidocaine presentations on shortage due to manufacturing delays.

Estimated Resupply Dates

- AuroMedics has 1% lidocaine 2 mL and 5 mL ampules on intermittent back order and the company is releasing product as it becomes available. There are short-dated 2 mL and 5 mL ampules available. The 1% lidocaine 30 mL vials are on intermittent back order and the company is releasing product as it becomes available. The 2% lidocaine 2 mL ampules and 2 mL vials are on intermittent back order and the company is releasing product as it becomes available. There are short-dated 2 mL ampules and vials available.
- Fresenius Kabi has 1% Xylocaine 50 mL vials on back order and the company estimates a release date of early-February 2021. The 1% lidocaine 10 mL vials are on back order and the company estimates a release date of January 2021. The 2% lidocaine 5 mL vials are on back order and the company estimates a release date of January 2021.
- Hikma has 1% lidocaine 5 mL vials and 2% lidocaine 5 mL vials on allocation. There are short-dated 1% lidocaine 50 mL vials available with an expiration date of May 2021. There are short-dated 2% lidocaine 50 mL vials available with an expiration date of September 2021.
- Pfizer has 0.5% lidocaine 50 mL flip top vials on back order and the company estimates a release date of January 2021. The 0.5% lidocaine 50 mL tear drop vials are on back order and the company estimates a release date of February 2021. The 1% lidocaine 5 mL preservative-free ampules are on back order and the company estimates a release date of January 2021. The 1% lidocaine 5 mL Ansyx syringes are on back order and the company estimates a release date of August 2021. The 1% lidocaine 50 mL vials are on back order and the company estimates a release date of January 2021. The 2% lidocaine 5 mL LifeShield syringes are available in limited supply. The 2% lidocaine 5 mL Ansyx syringes are on back order and the company estimates a release date of July 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=88>

Ceftolozane and Tazobactam Injection

January 22, 2021

Reason for the Shortage

- Merck has Zerbaxa on shortage due manufacturing issues related to sterility. They are the sole suppliers of ceftolozane and tazobactam injection.
- There is a global recall of Zerbaxa. Contact Merck at 1-800-672-6372.

Estimated Resupply Dates

- Merck has Zerbaxa 1.5 gram vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=705>

Amino Acid Products

January 22, 2021

Reason for the Shortage

- Baxter has amino acid presentations on shortage due to increased demand.
- BBraun has Plenamine on shortage due to active ingredient shortage. BBraun has discontinued the production of ProcalAmine and the company estimates supplies will be depleted by May 2021. BBraun has discontinued the production of FreAmine III and the company estimates supplies will be depleted by February 2021.
- ICU Medical has Aminosyn on shortage due to shortage of active ingredient.

Estimated Resupply Dates

- Baxter has Premasol 10% 500 mL, 1,000 mL, and 2,000 mL bottles on allocation. Prosol 20% 2,000 mL bottles are on allocation. Travasol 10% 500 mL, 1,000 mL, and 2,000 mL bottles are on back order and the company estimates release dates in late-March 2021. All Clinisol presentations are on allocation.
- BBraun has Trophamine 10% 500 mL glass containers, Plenamine 15% 1,000 mL flexible containers, and FreAmine III 10% 1,000 mL glass containers on allocation.
- ICU Medical has Aminosyn-PF 7% 500 mL containers on allocation. Aminosyn-PF 10% 1000 mL containers and both Aminosyn II presentations are available to contracted customers.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=564>

Vancomycin Hydrochloride Injection

January 24, 2021

Reason for the Shortage

- Alvogen has vancomycin injection available.
- Athenex has vancomycin injection available.
- AuroMedics did not provide a reason for the shortage.
- Baxter has vancomycin injection available.
- Fresenius Kabi has vancomycin injection available.
- Hikma did not provide a reason for the shortage.
- Mylan Institutional has vancomycin injection available.
- Pfizer has vancomycin vials on back order due to manufacturing delays.
- Samson Medical Technologies has vancomycin injection available.

- Sagent has vancomycin injection on shortage due to manufacturing delays.
- Slate Run Pharma has vancomycin injection available.
- Xellia has vancomycin injection available.

Estimated Resupply Dates

- Athenex has vancomycin 500 mg vials on back order and the company cannot estimate a release date.
- AuroMedics has vancomycin 1 gram vials on long-term back order and the company cannot estimate a release date.
- Hikma has vancomycin 5 gram vials and 10 gram vials on back order and the company estimates a release date of 4th quarter 2021.
- Mylan Institutional has vancomycin 5 gram vials on back order and the company cannot estimate a release date. The 1 gram and 10 gram vials are on back order and the company estimates a release date of late-February 2021 for the 1 gram vials and early-March 2021 for the 10 gram vials.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=25>

Sodium Bicarbonate Injection

January 24, 2021

Reason for the Shortage

- Amphastar has sodium bicarbonate injection available.
- Athenex is no longer marketing sodium bicarbonate. This was brought in for the shortage in conjunction with FDA.
- Exela has sodium bicarbonate available.
- Fresenius Kabi did not provide a reason for the shortage.
- Pfizer has sodium bicarbonate injection on shortage due to manufacturing delays and increased demand. The Neut vials were discontinued in December 2019.

Estimated Resupply Dates

- Fresenius Kabi has 8.4% sodium bicarbonate 50 mL vials on back order and the company estimates a release date of mid-February 2021.
- Pfizer has 8.4% sodium bicarbonate 50 mL LifeShield syringes on back order and the company cannot estimate a release date. The 4.2% sodium chloride 10 mL LifeShield syringes are on back order and the company estimates a release date of January 2022.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=293>

Midazolam Injection

January 24, 2021

Reason for the Shortage

- Akorn had midazolam injection on shortage due to increased demand.
- Athenex has midazolam injection on shortage due to increased demand.
- Avet has midazolam injection on shortage due to increased demand.
- Fresenius Kabi has midazolam injection on shortage due to increased demand. They are not marketing the 5 mg/mL 5 mL vials and 5 mg/mL 2 mL syringes.
- Hikma did not provide a reason for the shortage.

- Pfizer has midazolam injection on shortage due to manufacturing delays and increased demand.

Estimated Resupply Dates

- Akorn has midazolam 5 mg/mL 10 mL vials on back order and the company estimates a release date of mid-February 2021.
- Athenex has midazolam 5 mg/mL 5 mL and 10 mL vials on back order and the company estimates a release date of February 2021 for the 5 mL vials and late-January 2021 for the 10 mL vials.
- Hikma has midazolam 5 mg/mL 10 mL vials on allocation.
- Pfizer has midazolam 1 mg/mL 2 mL Carpuject syringes and 5 mg/mL 1 mL Carpuject syringes on back order and the company estimates a release date of June 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=576>

Cefotetan Disodium Injection

January 24, 2021

Reason for the Shortage

- BBraun did not provide a reason for the shortage.
- Fresenius Kabi has cefotetan injection available.
- Teligent has 2 gram vials available.

Estimated Resupply Dates

- BBraun has cefotetan 1 gram/50 mL and 2 gram/50 mL premixed bags on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=670>

Bupivacaine Injection

January 24, 2021

Reason for the Shortage

- AuroMedics has not provided a reason for the shortage.
- Fresenius Kabi had Sensorcaine on shortage due to increased demand for the product.
- Pfizer has bupivacaine on shortage due to manufacturing delays. Pfizer discontinued 0.5% bupivacaine 30 mL glass ampules in December 2017.

Estimated Resupply Dates

- Areva is temporarily importing 0.25% bupivacaine and 0.5% bupivacaine 5 mL and 10 mL ampules. FDA is allowing temporary importation of product from Italy manufactured by Areva's supplier, Fisiopharma. Details on how to obtain product and differences between the US and Italian labeling can be found at: <http://arevapharma.com/wp-content/uploads/2019/09/Dear-Health-Care-Provider-Letter-final.pdf>.
- AuroMedics has 0.25% bupivacaine 10 mL and 30 mL preservative-free vials on intermittent back order and the company is releasing product as it becomes available. The 0.75% bupivacaine 10 mL and 30 mL preservative-free vials are on intermittent back order and the company is releasing product as it becomes available.
- Pfizer has 0.25% 30 mL preservative-free vials available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=172>

Asparaginase *Erwinia chrysanthemi*

January 24, 2021

Reason for the Shortage

- Erwinaze supply disruption is due to ongoing manufacturing issues and capacity constraints at Porton Biopharma Limited, the sole manufacturer of Erwinaze. Erwinaze is distributed by Jazz Pharmaceuticals.

Estimated Resupply Dates

- Jazz Pharmaceuticals has Erwinaze 10,000 unit vials in 1 count and 5 count available in limited supply.
- There is a new process for ordering Erwinaze. Additional information regarding the new ordering process is available at www.erwinazesupply.com.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=482>

Acetylcysteine Oral and Inhalation Solution

January 24, 2021

Reason for the Shortage

- American Regent has acetylcysteine oral and inhalation solution on shortage due to manufacturing delays. They are not currently marketing the 200 mg/mL 30 mL vials.
- Arbor discontinued Cetylev effervescent tablets in April 2019.
- Fresenius Kabi did not provide a reason for the shortage.
- Pfizer has acetylcysteine oral and inhalation solution on shortage due to increased demand.
- Roxane Labs discontinued acetylcysteine oral and inhalation solution in April 2014.

Estimated Resupply Dates

- Pfizer has acetylcysteine 100 mg/mL 30 mL vials for inhalation and oral use available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=43>

Acetazolamide Injection

January 24, 2021

Reason for the Shortage

- Hikma did not provide a reason for the shortage.
- Mylan Institutional did not provide a reason for the shortage.
- X-Gen did not provide a reason for the shortage.

Estimated Resupply Dates

- Hikma has acetazolamide 500 mg vials on allocation.
- X-Gen has acetazolamide 500 mg vials on back order and the company estimates a release date of early-April 2021

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=528>

23.4% Sodium Chloride Injection

January 24, 2021

Reason for the Shortage

- Fresenius Kabi has 23.4% sodium chloride injection on shortage due to increased demand.
- Pfizer had 23.4% sodium chloride injection on shortage due to manufacturing delays.

Estimated Resupply Dates

- Fresenius Kabi has 23.4% sodium chloride 30 mL vials on back order and the company cannot estimate a release date. The 100 mL and 200 mL vials are on back order and the company estimates a release date of mid-March 2021 for the 100 mL vials and early- to mid-March 2021 for the 200 mL vials.
- Pfizer has 23.4% sodium chloride 100 mL vials available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=336>

Fentanyl Citrate Injection

January 25, 2021

Reason for the Shortage

- Akorn had fentanyl on shortage due to increased demand.
- Fresenius Kabi had fentanyl on shortage due to increased demand.
- Hikma had fentanyl injection on shortage due to supply and demand issues. They are not currently marketing fentanyl ampules, just vials.
- Pfizer has fentanyl injection on shortage due to increased demand. The 20 mL ampules were discontinued in September 2017.

Estimated Resupply Dates

- Pfizer has fentanyl 50 mcg/mL 2 mL Carpuject syringes on back order and the company estimates a release date of January 2023. The 20 mL and 50 mL vials are available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=315>

Etomidate Injection

January 25, 2021

Reason for the Shortage

- American Regent is not currently marketing etomidate.
- Athenex did not provide a reason for the current shortage.
- AuroMedics has etomidate injection on shortage due to increased demand.
- Fosun Pharma has etomidate injection available.
- Hikma has etomidate injection on shortage due to increased demand.
- Mylan Institutional has etomidate available.
- Par Sterile Products discontinued etomidate in early 2015.
- Pfizer discontinued etomidate ampules in October 2016. The LifeShield syringes were discontinued in August 2020.
- Sagent is no longer marketing etomidate.
- Zydus discontinued etomidate .

Estimated Resupply Dates

- Athenex has etomidate 2 mg/mL 10 mL and 20 mL vials on back order and the company cannot estimate a release date.
- AuroMedics has etomidate 2 mg/mL 10 mL vials on intermittent back order and the company is releasing product as it becomes available.

- Hikma has etomidate 2 mg/mL 20 mL vials on back order and the company estimates a release date of early-February 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=147>

Dexamethasone Sodium Phosphate Injection

January 25, 2021

Reason for the Shortage

- American Regent is not marketing dexamethasone sodium phosphate injection at this time.
- AuroMedics did not provide a reason for the shortage.
- Fresenius Kabi has dexamethasone sodium phosphate on shortage due to increased demand.
- Mylan Institutional has dexamethasone injection available.
- Hikma had dexamethasone injection on shortage due to increased demand.
- Somerset Therapeutics has 10 mg/mL 1 mL and 10 mL vials on shortage due to increased demand.

Estimated Resupply Dates

- AuroMedics has dexamethasone sodium phosphate 4 mg/mL 1 mL and 5 mL vials on long-term back order and the company cannot estimate a release date.
- Fresenius Kabi has dexamethasone sodium phosphate 4 mg/mL 1 mL vials and 10 mg/mL 1 mL preservative-free vials on back order and the company estimates a release date of early- to mid-February 2021.
- Hikma has dexamethasone sodium phosphate 4 mg/mL 1 mL vials and 10 mg/mL 1 mL vials on back order and the company estimates a release date of early-February 2021. The 4 mg/mL 5 mL vials are on allocation.
- Somerset Therapeutics has dexamethasone sodium phosphate 10 mg/mL vials on intermittent back order and the company is releasing product as it becomes available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=140>

Busulfan Injection

January 25, 2021

Reason for the Shortage

- American Regent did not provide a reason for the shortage.
- Amneal discontinued busulfan injection in 2020.
- Apotex has busulfan injection available.
- Armas Pharmaceuticals has busulfan injection available.
- Athenex did not provide a reason for the shortage.
- Mylan Institutional did not provide a reason for the shortage.
- Sagent has busulfan injection available.
- Teva discontinued busulfan injection in August 2020.
- Otsuka has Busulfex available.

Estimated Resupply Dates

- Athenex has busulfan 6 mg/mL 10 mL vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=509>

Ampicillin Sodium and Sulbactam Sodium Injection

January 25, 2021

Reason for the Shortage

- AuroMedics has ampicillin sulbactam vials on back order due to increased demand and manufacturing delays.
- Fresenius Kabi is not currently marketing ampicillin sulbactam injection.
- Meitheal Pharmaceuticals has ampicillin sulbactam available.
- Mylan Institutional did not provide a reason for the shortage.
- Pfizer has discontinued generic ampicillin sulbactam except for the 1.5 gram and 3 gram ADD-Vantage vials.
- Piramal Critical Care has ampicillin sulbactam available.
- Sagent has ampicillin sulbactam vials on back order due to manufacturing delays and increased demand.
- Sandoz discontinued ampicillin sulbactam.
- WG Critical Care states the shortage was due to increased demand.

Estimated Resupply Dates

- AuroMedics has ampicillin sulbactam 1.5 gram, 3 gram, and 15 gram vials on intermittent back order and the company is releasing product as it becomes available.
- Hikma has ampicillin sulbactam 1.5 gram vials, 3 gram vials, and 15 gram bulk vials on back order and the company cannot estimate a release date.
- Mylan Institutional has ampicillin sulbactam 1.5 gram vials and 15 gram bulk vials on back order and the company estimates a release date of late-January 2021.
- Sagent has ampicillin sulbactam 1.5 gram vials and 15 gram bulk vials on back order and the company estimates a release date of January 2021.
- Pfizer has ampicillin sulbactam 3 gram vials available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=159>

Phenelzine Sulfate Tablets

January 26, 2021

Reason for the Shortage

- Greenstone did not provide a reason for the shortage.
- Lupin has phenelzine tablets available.
- Pfizer has Nardil tablets on shortage due to manufacturing delay.

Estimated Resupply Dates

- Greenstone has phenelzine tablets on allocation.
- Pfizer has Nardil tablets on back order and the company estimates a release date in April 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=710>

Nefazodone Tablets

January 26, 2021

Reason for the Shortage

- Teva has nefazodone on shortage due to raw ingredient supply issues. They are the sole suppliers of nefazodone tablets.

Estimated Resupply Dates

- Teva has all presentations temporarily unavailable and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=679>

Mycophenolate Mofetil Capsules and Tablets

January 28, 2021

Reason for the Shortage

- Accord has mycophenolate capsules and tablets available.
- Ascend did not provide a reason for the shortage.
- Hikma did not provide a reason for the shortage.
- Mylan has mycophenolate capsules and tablets available.
- Genentech has Cellcept available.
- Sandoz did not provide a reason for the shortage.
- Teva has mycophenolate capsules available.

Estimated Resupply Dates

- Ascend has all mycophenolate mofetil presentations on intermittent back order and the company is releasing product as it becomes available.
- Hikma has mycophenolate mofetil 250 mg capsules in 100 count and 500 count and 500 mg tablets in 100 count and 500 count on allocation.
- Sandoz has mycophenolate mofetil 250 mg capsules in 1,440 count bottles on back order and the company cannot estimate a release date. The 500 mg tablets in 500 count bottles are available with short expiration dating (May 2021).

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=448>

Levetiracetam Injection

January 28, 2021

Reason for the Shortage

- Athenex has levetiracetam injection available.
- AuroMedics has levetiracetam injection available.
- Dr. Reddy's has levetiracetam injection available.
- Fresenius Kabi did not provide a reason for the shortage.
- Hikma has levetiracetam injection available.
- Mylan has levetiracetam injection available.
- Pfizer has levetiracetam injection on shortage due to manufacturing delays.
- Sagent did not provide a reason for the shortage.
- Sun Pharma are not manufacturing levetiracetam injection at this time.

- UCB has product available.
- X-Gen has levetiracetam injection available.

Estimated Resupply Dates

- Fresenius Kabi has levetiracetam 100 mg/mL 5 mL vials on back order and the company estimates a release date in mid-February 2021.
- Sagent has levetiracetam 100 mg/mL 5 mL vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=84>

Hydrocortisone Oral Tablets

January 28, 2021

Reason for the Shortage

- Amneal discontinued all hydrocortisone tablets presentations in the first half of 2020.
- Greenstone did not provide a reason for the shortage.
- Pfizer has Cortef tablets available.

Estimated Resupply Dates

- Greenstone has hydrocortisone 10 mg and 20 mg tablets on allocation. The 5 mg tablets are on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=648>

Cisatracurium Besylate Injection

January 28, 2021

Reason for the Shortage

- Fresenius Kabi has cisatracurium on shortage due to increased demand.
- Meitheal Pharmaceuticals has cisatracurium on shortage due to increased demand. One lot of cisatracurium 2 mg/mL 5 mL vials has been recalled due to mislabeling. Lot C11507A has the correct carton information, but the vials are mislabeled as phenylephrine 10 mg/mL 10 mL injection. More information can be found at: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/meitheal-pharmaceuticals-inc-issues-voluntary-nationwide-recall-cisatracurium-besylate-injection-usp?utm_medium=email&utm_source=govdelivery
- Pfizer had cisatracurium on shortage due to increased demand.
- Sandoz had cisatracurium on shortage due to increased demand.
- Somerset has cisatracurium on shortage due to increased demand.
- Teva had cisatracurium on shortage due to increased demand.
- AbbVie did not provide a reason for the shortage of Nimbex.

Estimated Resupply Dates

- Fresenius Kabi has cisatracurium 10 mg/mL 20 mL vials and 2 mg/mL 5 mL and 10 mL vials on back order and the company estimates a release date of early- to mid-February 2021 for the 2 mg/mL 5 mL vials and late-February 2021 for the 10 mg/mL 20 mL vials and 2 mg/mL 10 mL vials. Check wholesalers for inventory.
- Pfizer has cisatracurium 2 mg/mL 10 mL vials and 10 mg/mL 20 mL vials available in limited supply.

- Sandoz has short-dated cisatracurium available with an expiration date of October 2021 for the 2 mg/mL 5 mL vials and 10 mg/mL 20 mL vials and November 2021 for the 2 mg/mL 10 mL vials.
- Somerset has cisatracurium 2 mg/mL 5 mL vials on back order and the company cannot estimate a release date. The 2 mg/mL 10 mL vials and 10 mg/mL 20 mL vials are on intermittent back order and the company is releasing product as it becomes available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=652>

Amphetamine Mixed Salts, Immediate-Release Tablets

January 28, 2021

Reason for the Shortage

- Aurobindo refuses to provide updated availability information.
- Mallinckrodt has amphetamine mixed salts available.
- Mylan did not provide a reason for the shortage
- Sun Pharma discontinued amphetamine mixed salts in 2019.
- Teva did not provide a reason for the generic amphetamine mixed salts shortage. The company has brand name Adderall available.
- Zydus did not provide a reason for the shortage.

Estimated Resupply Dates

- Mylan has amphetamine mixed salts 5 mg, 7.5 mg, 10 mg, 12.5mg, 15 mg, 20 mg, and 30 mg immediate release tablets on back order and the company cannot estimate a release date.
- Teva has amphetamine mixed salts immediate-release 20 mg tablets on back order and the company estimates a release date of late-February 2021. The 30 mg immediate-release tablets are on intermittent back order and the company is releasing supplies as they become available.
- Zydus has amphetamine mixed salts immediate-release 12.5 mg and 30 mg tablets on back order and the company cannot estimate a release date. All other presentations are on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=535>

0.9% Sodium Chloride Small Volume Bags (< 150 mL)

January 28, 2021

Reason for the Shortage

- Baxter has 0.9% sodium chloride small volume bags on back order due to manufacturing delay and increased demand.
- BBraun has 0.9% sodium chloride small volume bags available.
- BD did not provide a reason for the shortage.
- Fresenius Kabi did not provide a reason for the shortage.
- ICU Medical states the shortage was due to manufacturing delay.
- Pfizer had 0.9% sodium chloride small volume presentations on shortage due to increased demand.

Estimated Resupply Dates

- Baxter has 0.9% sodium chloride 50 mL minibags in single packs, 100 mL minibags in single packs, and 100 mL minibags in quad packs available in limited supply.
- BD has 0.9% sodium chloride 50 mL and 100 mL PVC/DEHP-free bags on allocation.

- Fresenius Kabi has 0.9% sodium chloride 100 mL vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=352>

Valsartan and Hydrochlorothiazide Tablets

January 29, 2021

Reason for the Shortage

- Several drug products containing valsartan were recalled due to an unexpected impurity found in the active pharmaceutical ingredient manufactured by a third party. The impurity is N-nitrosodimethylamine (NDMA) and is classified as a probably human carcinogen. Additional information is available at <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613532.htm>.
- Solco and Teva valsartan/hydrochlorothiazide tablets were affected by the recall. Detailed information on the products is available at <https://www.fda.gov/downloads/Drugs/DrugSafety/UCM615703.pdf>.
- Solco and Teva discontinued valsartan/hydrochlorothiazide tablets in July 2018.
- Aurobindo refused to provide updated availability information.
- Lupin has valsartan/hydrochlorothiazide tablets on back order because they are holding and testing product for impurities.
- Macleods has valsartan/hydrochlorothiazide tablets available.
- Repackagers may have some presentations affected depending on the source supplier.

Estimated Resupply Dates

- Alembic has all valsartan/hydrochlorothiazide presentations on allocation.
- Lupin has all valsartan/hydrochlorothiazide presentations on back order and the company cannot estimate a release date.
- Mylan has all valsartan/hydrochlorothiazide tablet presentations in 500 count bottles on back order and the company cannot estimate release dates.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=445>

Sulfasalazine Enteric-Coated and Immediate-Release Tablets

January 29, 2021

Reason for the Shortage

- Greenstone did not provide a reason for the shortage.
- Teva did not provide a reason for the shortage.
- Pfizer has Azulfidine available.

Estimated Resupply Dates

- Greenstone has sulfasalazine enteric-coated 500 mg tablets and immediate-release 500 mg tablets in 100 count bottles on intermittent back order and the company is releasing supplies as they become available. The enteric-coated 500 mg tablets and immediate-release 500 mg tablets in 300 count bottles are on back order and the company cannot estimate release dates.
- Teva has sulfasalazine immediate-release tablets on back order and the company estimates a release date in early-February 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=625>

Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment

January 29, 2021

Reason for the Shortage

- Bausch Health has neomycin/polymyxin B sulfates/dexamethasone ophthalmic ointment available.
- Novartis has Maxitrol ointment available.
- Perrigo did not provide a reason for the shortage.
- Sandoz has neomycin/polymyxin B sulfates/dexamethasone ophthalmic ointment available.

Estimated Resupply Dates

- Perrigo has temporarily discontinued neomycin/polymyxin B/dexamethasone ophthalmic ointment in 3.5 gram tubes and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=645>

Enoxaparin Sodium Injection

January 29, 2021

Reason for the Shortage

- Amphastar has enoxaparin available.
- Apotex has enoxaparin available.
- Fresenius Kabi did not provide a reason for the shortage.
- Meitheal has enoxaparin available.
- Sanofi-Aventis did not provide a reason for the shortage.
- Teva has enoxaparin available.
- Winthrop did not provide a reason for the shortage.

Estimated Resupply Dates

- Fresenius Kabi has enoxaparin 30 mg prefilled syringes (NDC 63323-0559-93) available with short expiration dating (< 5 months). The 60 mg syringes (NDC 63323-0566-98) are also available with short expiration dating (< 8 months).
- Sanofi-Aventis has all Lovenox presentations on allocation.
- Winthrop has all enoxaparin presentations on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=466>

Clindamycin Phosphate Injection

February 1, 2021

Reason for the Shortage

- Alvogen injectable generic products including clindamycin are being marketed under the brand, Almaject Inc., as of October 1, 2019. The NDC numbers for these products have changed.
- Akorn discontinued clindamycin injection in early 2020.
- Baxter has clindamycin injection on shortage due to manufacturing delays.
- Fresenius Kabi did not provide a reason for the shortage.
- Pfizer did not provide a reason for the shortages. Pfizer discontinued Cleocin premixed bags in 2018 and ADD-Vantage vials in 2020.

- Sagent did not provide a reason for the shortage.
- Sandoz did not provide a reason for the shortage.

Estimated Resupply Dates

- Almaject has short-dated clindamycin phosphate 150 mg/mL 2 mL vials available with an expiration date of November 2021.
- Baxter has all clindamycin phosphate injection presentations on intermittent back order and the company is releasing product as it becomes available.
- Pfizer has Cleocin 150 mg/mL 60 mL vials available in limited supply.
- Sagent has clindamycin phosphate 150 mg/mL 60 mL vials on back order and the company estimates a release date of August 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=97>

Chlorothiazide Sodium Injection

February 1, 2021

Reason for the Shortage

- Akorn has chlorothiazide on allocation due to increased demand.
- American Regent did not provide a reason for the shortage.
- Fresenius Kabi has chlorothiazide injection available.
- Mylan discontinued chlorothiazide injection in May 2020.
- Sagent has chlorothiazide injection on shortage due to manufacturing delays.
- Sun Pharma did not provide a reason for the shortage.

Estimated Resupply Dates

- Akorn has chlorothiazide 500 mg vials on back order and the company estimates a release date of late-March 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=638>

Cefoxitin Sodium Injection

February 1, 2021

Reason for the Shortage

- Apotex discontinued cefoxitin in late-2020.
- BBraun has cefoxitin available.
- Fresenius Kabi has cefoxitin available.
- Hikma did not provide a reason for the shortage.
- Sagent had cefoxitin on shortage due to increased demand and manufacturing delay.
- WG Critical Care has cefoxitin available.

Estimated Resupply Dates

- Hikma has cefoxitin 10 gram vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=271>

Sterile Mineral Oil

February 2, 2021

Available Products

- There is insufficient supply for usual ordering.

Estimated Resupply Dates

- Fresenius Kabi has Muri-Lube 2 mL and 10 mL vials on back order and the company estimates release dates of early-February 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=690>

Ropivacaine Injection

February 2, 2021

Reason for the Shortage

- Akorn had ropivacaine on shortage due to increased demand.
- AuroMedics did not provide a reason for the shortage.
- Fresenius Kabi has Naropin on shortage due to increased demand and manufacturing delays.
- Pfizer has ropivacaine on shortage due to increase demand.
- Sagent had ropivacaine on shortage due to manufacturing delays
- Somerset Therapeutics has ropivacaine 5 mg/mL 30 mL vials available.

Estimated Resupply Dates

- AuroMedics has ropivacaine 2 mg/mL 20 mL vials and 7.5 mg/mL 20 mL vials on intermittent back order and the company is releasing product as it becomes available.
- Fresenius Kabi has Naropin 2 mg/mL 20 mL vials on back order and the company estimates a release date of late-February 2021. The 2 mg/mL 100 mL bottles are on back order and the company estimates a release date of early-March 2021. The 2 mg/mL 200 mL bottles are on back order and the company cannot estimate a release date. The 5 mg/mL 200 mL bottles are on back order and the company estimates a release date of early-March 2021.
- Pfizer has ropivacaine 2 mg/mL 10 mL and 20 mL vials on back order and the company estimates a release date of February 2021. The 10 mg/mL 20 mL vials are on back order and the company estimates a release date of February 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=384>

Nalbuphine Injection

February 2, 2021

Reason for the Shortage

- Pfizer has nalbuphine on shortage due to manufacturing delays.

Estimated Resupply Dates

- Pfizer has nalbuphine 10 mg/mL 10 mL vials on back order and the company estimates a release date of February 2021. The 10 mg/mL 1 mL ampules are available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=599>

Morphine Injection

February 2, 2021

Reason for the Shortage

- Fresenius Kabi has morphine injection on shortage due to manufacturing delays.
- Astramorph injection has been unavailable since 2012. Fresenius Kabi changed manufacturing sites and cannot estimate if Astramorph will return.
- Pfizer has a shortage of several prefilled syringe products, including morphine, starting in late-July 2017 due to issues at a manufacturing facility. Pfizer discontinued morphine iSecure syringes in February 2020. Pfizer discontinued morphine 25 mg/mL 1 mL preservative-free vials in late-2020.
- Hikma did not provide a reason for the shortage.
- Piramal Critical Care did not provide a reason for the shortage.

Estimated Resupply Dates

- Fresenius Kabi has morphine 4 mg/mL 1 mL vials on back order and the company estimates a release date of mid-February 2021. The 8 mg/mL 1 mL vials are on back order and the company estimates a release date of mid-February 2021. The 4 mg/mL 1 mL syringes are on back order and the company cannot estimate a release date.
- Hikma has short-dated Infumorph 10 mg/mL 20 mL ampules and 25 mg/mL 20 mL ampules available with an expiration date of April 2021.
- Piramal has Mitigo 10 mg/mL 20 mL preservative-free vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=41>

Leucovorin Calcium Injection

February 2, 2021

Reason for the Shortage

- Fresenius Kabi had leucovorin on shortage due to manufacturing delays and increased demand.
- Hikma did not provide a reason for the current shortage.
- Mylan did not provide a reason for the current shortage.
- Sagent has leucovorin on shortage due to manufacturing delays.
- Teva has leucovorin available.

Estimated Resupply Dates

- Hikma has leucovorin 350 mg vials are on allocation.
- Mylan Institutional has 50 mg vials on back order and the company estimates a release date of mid- to late-April 2021.
- Sagent has leucovorin 50 mg vials on back order and the company cannot estimate a release date. The 350 mg and 500 mg vials on back order and the company estimates a release date of February 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=35>

Heparin Sodium Premixed Bags

February 2, 2021

Reason for the Shortage

- Baxter has heparin premixes on back order due to manufacturing delays.

- B Braun had heparin premixes on back order due to manufacturing delays.
- Fresenius Kabi had put heparin on a protective allocation due to a potential shortage of raw ingredient. The letter describing this in detail is available at the following link: <https://www.fresenius-kabi.com/us/news/fresenius-kabi-responds-to-a-potential-shortage-of-heparin>.
- Pfizer has heparin on shortage due to manufacturing delays.

Estimated Resupply Dates

- Baxter has heparin 2,000 units/1,000 mL in 0.9% sodium chloride premixed bags on back order and the company estimates a release date of mid-February 2021.
- Fresenius Kabi has short-dated 25,000 units/250 mL in 0.45% sodium chloride premixed bags available with an expiration date of < 8 months. The 25,000 units/500 mL in 5% dextrose premixed bags are on back order and the company estimates a release date of early-February 2021.
- Pfizer has heparin 25,000 units/250 mL in 5% dextrose premixed bags on back order and the company estimates a release date of February 2021. The 2,000 unit/1,000 mL in 0.9% sodium chloride premixed bags are available in limited supply. The 25,000 units/500 mL in 0.45% sodium chloride premixed bags are available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=468>

Haloperidol Lactate Injection

February 2, 2021

Reason for the Shortage

- Fresenius Kabi has haloperidol lactate injection on shortage due to increased demand.
- Hikma did not provide a reason for the shortage.
- Janssen discontinued Haldol injection in November 2020.
- Mylan Institutional did not provide a reason for the shortage.
- Patriot Pharmaceuticals discontinued haloperidol lactate injection in November 2020.
- Sagent has haloperidol lactate injection on shortage due to increased demand.

Estimated Resupply Dates

- Fresenius Kabi has haloperidol lactate injection 5 mg/mL vials on back order and the company estimates a release date of early-February 2021.
- Hikma has haloperidol lactate injection 5 mg/mL vials on back order and the company estimates a release date of 4th quarter 2021.
- Mylan Institutional has haloperidol lactate injection 5 mg/mL vials on back order and the company estimates a release date of early-March 2021.
- Sagent has haloperidol lactate 5 mg/mL 1 mL vials available on limited allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=698>

Furosemide Injection

February 2, 2021

Reason for the Shortage

- American Regent is not actively marketing furosemide injection.
- Amneal discontinued furosemide injection.

- AuroMedics has furosemide injection on shortage due to shipping delays.
- Avet Pharmaceuticals has furosemide injection available.
- Baxter has furosemide injection available.
- Fresenius Kabi did not provide a reason for the shortage.
- Pfizer had furosemide injection on shortage due to manufacturing delays and increased demand.

Estimated Resupply Dates

- AuroMedics has furosemide 10 mg/mL 2 mL, 4 mL, and 10 mL vials on intermittent back order and the company is releasing product as it becomes available.
- Fresenius Kabi has furosemide 10 mg/mL 4 mL and 10 mL vials on back order and the company estimates a release date of late-February 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=323>

Fluorescein Sodium Ophthalmic Strips

February 2, 2021

Reason for the Shortage

- Hub has Bio-Glo on shortage due to shipping delays.
- Akorn did not provide a reason for the shortage.

Estimated Resupply Dates

- Akorn has Ful-Glo 1 mg strips on back order and the company estimates a release date of mid-February 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=362>

Famotidine Tablets

February 2, 2021

Reason for the Shortage

- Alembic has famotidine tablets on allocation due to increased demand.
- Aurobindo refuses to provide availability information.
- Major did not provide a reason for the shortage.
- Mylan discontinued famotidine tablets in all presentations in April 2019.
- Teva has famotidine tablets on shortage due to increased demand.
- Bausch Health did not provide a reason for the shortage.
- Dr. Reddy's discontinued famotidine tablets in all presentations.

Estimated Resupply Dates

- Alembic has famotidine tablets on allocation.
- Major has famotidine 20 mg tablets on back order and the company estimates a release date of mid-February 2021.
- Teva has famotidine tablets on intermittent back order and the company is releasing product as it becomes available.
- Bausch Health has Pepcid 20 mg tablets in 100 count on back order and the company estimates a release date of late-April 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=616>

Famotidine Injection

February 2, 2021

Reason for the Shortage

- Baxter had famotidine injection on shortage due to manufacturing delays.
- Fresenius Kabi did not provide a reason for the shortage.
- Hikma did not provide a reason for the shortage.
- Mylan Institutional did not provide a reason for the shortage.

Estimated Resupply Dates

- Fresenius Kabi has famotidine 10 mg/mL 4 mL vials on back order and the company estimates a release date of early- to mid-March 2021.
- Hikma has famotidine 10 mg/mL 20 mL vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=656>

Docusate Sodium Oral Liquid in Bulk Bottles

February 2, 2021

Reason for the Shortage

- Akorn did not provide a reason for the shortage.
- Geri-Care had a contract manufacturer shut down. The company has discontinued Diocto syrup and liquid.
- Lannett has Silace available.
- Docusate sodium 10 mL unit dose cups are not affected.

Estimated Resupply Dates

- Akorn has Docu liquid 150 mg/15 mL 473 mL bottles on back order and the company estimates a release date of March 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=585>

Dobutamine Injection

February 2, 2021

- Reason for the Shortage
- Baxter had dobutamine on shortage due to increased demand.
- Pfizer has dobutamine on shortage due to manufacturing delays. The latex-free vials are no longer being marketed.

Estimated Resupply Dates

- Pfizer has short-dated dobutamine 4 mg/mL in 250 mL bags available with an expiration date of May 2021. There are short-dated 2 mg/mL in 250 mL bags available with an expiration date of June 2021. The 1 mg/mL 250 mL bags are on back order and the company estimates a release date of April 2021. The 12.5 mg/mL 20 mL vials in 1 count and 10 count are available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=296>

Chlorprocaine Hydrochloride Injection

February 2, 2021

Reason for the Shortage

- Fresenius Kabi did not provide a reason for the shortage.
- Hikma did not provide a reason for the shortage.

Estimated Resupply Dates

- Fresenius Kabi has Nesacaine-MPF 30 mg/mL 20 mL vials on back order and the company estimates a release date of early- to mid-March 2021.
- Hikma has chlorprocaine 20 mg/mL 20 mL preservative-free vials are on back order and the company cannot estimate a release date. The 30 mg/mL 20 mL preservative-free vials are on back order and the company estimates a release date of early- to mid-February 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=701>

Amiodarone Injection

February 2, 2021

Reason for the Shortage

- Baxter has Nexterone premixed bags available.
- Fresenius Kabi did not provide a reason for the shortage.
- Hikma did not provide a reason for the shortage; however, the 50 mg/mL, 3 mL 10 count presentation was discontinued in December 2018.
- Mylan Institutional did not provide a reason for the shortage.
- Sagent discontinued amiodarone 50 mg/mL 3 mL syringes in June 2019.

Estimated Resupply Dates

- AuroMedics has amiodarone 50 mg/mL 3 mL, 9 mL, and 18 mL vials on long-term back order and the company cannot estimate a release date.
- Fresenius Kabi has amiodarone 50 mg/mL 9 mL vials on back order and the company estimates a release date of early- to mid-March 2021. There are short-dated 3 mL vials available with an expiration date of < 8 months.
- Hikma has amiodarone 50 mg/mL 3 mL vials on back order and the company estimates a release date of early- to mid-February 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=374>

Alprostadil Urethral Suppositories

February 2, 2021

Reason for the Shortage

- Mylan did not provide a reason for the shortage.

Estimated Resupply Dates

- Mylan has Muse 125 mcg and 250 mcg suppositories on back order and the company estimates a release date of early-February 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=605>

Multiple Vitamins for Infusion

February 3, 2021

Reason for the Shortage

- Baxter has Infuvite on shortage due to 3rd party supplier manufacturing delays. Baxter provided a new Dear Customer letter that can be found at:
https://www.nutritioncare.org/uploadedFiles/Documents/Guidelines_and_Clinical_Resources/Shortages/Baxter%20Customer%20Letter%20Infuvite%2001.22.21.pdf.
- Pfizer states the shortage of M.V.I. is due to manufacturing delays.

Estimated Resupply Dates

- Baxter has all Infuvite presentations on back order and the company cannot estimate a release date.
- Pfizer has M.V.I. Adult 2 X 5 mL Dual vials, M.V.I. Adult 2 X 50 mL vials, and Pediatric 5 mL vials on back order and the company estimates a release date of September 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=69>

Prochlorperazine Maleate Tablets

February 4, 2021

Reason for the Shortage

- Cadista had prochlorperazine maleate tablets on shortage due to increased demand.
- Mylan did not provide a reason for the shortage.[2]
- Mylan Institutional discontinued the prochlorperazine maleate unit-dose presentations in August 2019.

Estimated Resupply Dates

- Mylan has prochlorperazine maleate 5 mg and 10 mg tablets in 100 count bottles on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=549>

Pantoprazole Injection

February 4, 2021

Reason for the Shortage

- AuroMedics had pantoprazole injection on shortage due to increased demand.
- Hikma did not provide a reason for the shortage.
- Pfizer had Protonix injection on shortage due to manufacturing delays.

Estimated Resupply Dates

- AuroMedics has pantoprazole 40 mg vials on intermittent back order and the company is releasing product as it becomes available.
- Hikma has pantoprazole 40 mg vials on allocation.
- Pfizer has Protonix 40 mg vials in 10 count and 25 count available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=550>

Mepivacaine Injection

February 4, 2021

Reason for the Shortage

- Fresenius Kabi has Polocaine on shortaged due to manufacturing delays.
- Pfizer states the reason for the shortage is manufacturing delays.

Estimated Resupply Dates

- Fresenius Kabi has 1.5% Polocaine-MPF 30 mL vials on back order and the company estimates a release date of early-March 2021. The 2% Polocaine-MPF 20 mL vials are on back order and the company estimates a release date of early- to mid-March 2021.
- Pfizer has 2% Carbocaine 20 mL preservative-free vials, 1% Carbocaine 30 mL preservative-free vials, and 1.5% Carbocaine 30 mL preservative-free vials on back order and the company estimates a release date of January 2022. The 2% Carbocaine 50 mL multiple-dose vials are on back order and the company estimates a release date of January 2022.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=331>

Meperidine Hydrochloride Injection

February 4, 2021

Reason for the Shortage

- Hikma did not provide a reason for the shortage.
- Pfizer has Demerol injection on shortage due to manufacturing delays. Demerol 50 mg/mL 0.5 mL, 1 mL ampules, and 1.5 mL ampules and 100 mg/mL 1 mL ampules in July 2020.
- ICU Medical discontinued meperidine 30 mL PCA vials.

Estimated Resupply Dates

- Pfizer has Demerol 50 mg/mL 2 mL ampules on back order and the company estimates a release date of February 2023. The 100 mg/mL 20 mL vials are on back order and the company estimates a release date of February 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=347>

Lisinopril Tablets

February 4, 2021

Reason for the Shortage

- Exelan, Lupin, and Teva did not provide a reason for the shortage.
- Major has lisinopril tablets available.

Estimated Resupply Dates

- Exelan has lisinopril 5 mg tablets in 1000 count and 20 mg tablets in 5000 count bottles on back order and the company cannot estimate a release date. The 40 mg tablets in 180 count bottles are on back order and the company cannot estimate a release date.
- Lupin has lisinopril 2.5 mg tablets in 100 count and 500 count bottles, 5 mg tablets in 100 count and 1000 count bottles, 10 mg tablets in 100 count and 1000 count bottles, 20 mg tablets in 100 count bottles, 30 mg tablets in 100 count and 500 count bottles, and 40 mg tablets in 100 count and 1000 count bottles on back order and the company cannot estimate a release date.

- Teva has most lisinopril tablet presentations on back order and the company estimates release dates in mid-February 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=666>

Hydroxychloroquine Sulfate Tablets

February 4, 2021

Reason for the Shortage

- Amneal had hydroxychloroquine 200 mg tablets on shortage due to increased demand.
- Concordia has Plaquenil 200 mg tablets available.
- Dr. Reddy's did not provide a reason for the shortage.
- Major has discontinued hydroxychloroquine tablets.
- Mylan has hydroxychloroquine 200 mg tablets available.
- Prasco had hydroxychloroquine 200 mg tablets on shortage due to increased demand.
- Rising has hydroxychloroquine tablets available and the company is shipping to forecast.
- Sandoz did not provide a reason for the shortage.
- Sun Pharma did not provide a reason for the shortage.
- Teva has hydroxychloroquine tablets on shortage due to increased demand.
- Zydus has hydroxychloroquine 200 mg tablets on shortage due to increased demand.

Estimated Resupply Dates

- Sandoz has hydroxychloroquine 200 mg tablets in 500 count bottles on back order and the company cannot estimate a release date.
- Teva has hydroxychloroquine 200 mg tablets in 100 count bottles on intermittent back order and the company is releasing supplies as they become available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=646>

Eptifibatide Injection

February 4, 2021

Reason for the Shortage

- Accord has temporarily discontinued eptifibatide injection.
- Akorn is not currently marketing eptifibatide.
- Amneal did not provide a reason for the shortage.
- Auromedics did not provide a reason for the shortage.
- Baxter has eptifibatide injection available.
- Merck discontinued Integrilin in October 2020. Wholesalers may continue to sell inventory until product expires.
- Mylan has eptifibatide available.
- Sagent states the shortage is due to manufacturing delay.
- Slate Run has eptifibatide injection available.

Estimated Resupply Dates

- Amneal has eptifibatide 0.75 mg/mL in 100 mL vials and 2 mg/mL in 10 mL vials on back order and the company cannot estimate a release date.

- Auromedics has eptifibatide 2 mg/mL in 10 mL vials on intermittent back order and the company is releasing supplies as they become available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=661>

Doxorubicin Injection

February 4, 2021

Reason for the Shortage

- Athenex did not provide a reason for the shortage.[1]
- Fresenius Kabi has doxorubicin available. Fresenius Kabi discontinued the 10 mL vial in October 2020.[2]
- Hikma did not provide a reason for the shortage.[3]
- Mylan Institutional discontinued doxorubicin 10 mg lyophilized powder for injection in early 2019. The 50 mg vials are available.[4]
- Teva did not provide a reason for the shortage.[6-7]
- Pfizer has doxorubicin on shortage due to increased demand.[5]
- Caraco has discontinued doxorubicin solution for injection 25 mL and 100 mL vials.[8]
- Sagent discontinued doxorubicin in late-2020.

Estimated Resupply Dates

- Athenex has doxorubicin 2 mg/mL 25 mL and 100 mL vials on back order and the company cannot estimate a release date.[1]
- Teva has doxorubicin 2 mg/mL 10 mL, 25 mL, and 100 mL vials on back order and the company estimates a release date of March 2021 for the 10 mL vials and February 2021 for the 25 mL and 100 mL vials.[6]
- Hikma has Adriamycin 2 mg/mL 10 mL vials on back order and the company estimates a release date of mid-March 2021. The 100 mL vials are on allocation.[3]
- Pfizer has doxorubicin 2 mg/mL 75 mL vials available in limited supply.[5]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=108>

Cyclopentolate Hydrochloride Ophthalmic Solution

February 4, 2021

Reason for the Shortage

- Akorn did not provide a reason for the shortage.
- Sandoz did not provide a reason for the shortage.
- Alcon did not provide a reason for the shortage.
- Bausch Health did not provide a reason for the shortage.

Estimated Resupply Dates

- Akorn has all cyclopentolate presentations temporarily unavailable.
- Alcon has all Cyclogyl presentations on back order and the company estimates a release date in late-March 2021.
- Bausch Health has 1% cyclopentolate 15 mL bottles on back order and the company estimates a release date of early-April 2021.

- Sandoz has 1% cyclopentolate 2 mL and 15 mL bottles on back order and the company estimates a release date of late-April 2021 for the 2 mL bottles and early- to mid-February 2021 for the 15 mL bottles.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=668>

Cyclopentolate Hydrochloride Ophthalmic Solution

February 4, 2021

Reason for the Shortage

- Akorn did not provide a reason for the shortage.
- Sandoz did not provide a reason for the shortage.
- Alcon did not provide a reason for the shortage.
- Bausch Health did not provide a reason for the shortage.

Estimated Resupply Dates

- Akorn has all cyclopentolate presentations temporarily unavailable.
- Alcon has all Cyclogyl presentations on back order and the company estimates a release date in late-March 2021.
- Bausch Health has 1% cyclopentolate 15 mL bottles on back order and the company estimates a release date of early-April 2021.
- Sandoz has 1% cyclopentolate 2 mL and 15 mL bottles on back order and the company estimates a release date of late-April 2021 for the 2 mL bottles and early- to mid-February 2021 for the 15 mL bottles.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=668>

Chlordiazepoxide Capsules

February 4, 2021

Reason for the Shortage

- Mylan did not provide a reason for the shortage.
- Teva did not provide a reason for the shortage.

Estimated Resupply Dates

- Mylan has chlordiazepoxide 5 mg capsules, 10 mg capsules, and 25 mg capsules in 100 count unit-dose blister packs on back order and the company cannot estimate a release date.
- Teva has chlordiazepoxide 10 mg capsules in 500 count bottles and 25 mg capsules in 100 count bottles on back order and the company estimates a release date of late-March 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=612>

Amyl Nitrite Inhalation

February 4, 2021

Reason for the Shortage

- James Alexander resumed manufacturing amyl nitrite in January 2021.

Estimated Resupply Dates

- James Alexander has amyl nitrite inhalation on back order and the company estimates a release date in April 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=505>

Temazepam Capsules

February 5, 2021

Reason for the Shortage

- Ascend did not provide a reason for the shortage.
- Major has discontinued temazepam 7.5 mg tablets.
- Mylan did not provide a reason for the shortage.
- Sun Pharma discontinued temazepam capsules in 2019.
- Teva has temazepam tablets available.
- Mallinckrodt has Restoril capsules available.
- Mylan Institutional discontinued temazepam capsules in unit-dose packaging.

Estimated Resupply Dates

- Ascend has temazepam 15 mg and 30 mg capsules in 500 count bottles on intermittent back order and the company is releasing supplies as they become available.
- Mylan has all presentations of temazepam capsules on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=503>

Sertraline Oral Tablets

February 5, 2021

Reason for the Shortage

- Accord is unable to obtain active pharmaceutical ingredient to manufacture sertraline due to effects of COVID-19.
- Aurobindo refuses to provide availability information.
- Cipla USA has sertraline tablets available.
- Exelan Pharmaceuticals did not provide a reason for the shortage.
- Greenstone did not provide a reason for the shortage.
- Lupin has product on shortage due to increased demand and lack of supply of the active pharmaceutical ingredient.
- Pfizer currently has enough product to supply historical demand.

Estimated Resupply Dates

- Accord has sertraline 50 mg and 100 mg tablets in 500 count bottles on intermittent back order and the company is releasing supplies as they become available.
- Exelan Pharmaceuticals has sertraline 25 mg tablets in 180 count bottles, 50 mg tablets in 60 count bottles, 50 mg tablets in 90 count bottles, 50 mg tablets in 180 count bottles, and 100 mg tablets in 100 count bottles on back order and the company cannot estimate release dates. The 50 mg tablets in 500 count are on back order and the company estimates a release date of early-February 2021.

- Greenstone has sertraline 50 mg tablets in 100 count bottles, 50 mg tablets in 500 count bottles, and 100 mg tablets in 500 count bottles on back order and the company estimates release dates in March 2022. All other presentations are on allocation.
- Lupin has sertraline 100 mg tablets in 30, 90, 500, and 5,000 count bottles on intermittent back order and the company is releasing supplies as they become available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=660>

Menotropins - Follicle Stimulating Hormone and Luteinizing Hormone

February 5, 2021

Reason for the Shortage

- Ferring did not provide a reason for the shortage.

Estimated Resupply Dates

- Ferring has Menopur on emergency allocation. The company estimates additional product will be available in February 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=700>

Lorazepam Tablets

February 5, 2021

Reason for the Shortage

- Aurobindo refuses to provide availability information.
- Bausch Health has Ativan tablets available.
- Leading has lorazepam tablet presentations available and is shipping supplies regularly.
- Major has lorazepam tablets available.
- Mylan has discontinued all bottled presentations.
- Mylan Institutional discontinued all unit-dose blister pack presentations.
- Sandoz discontinued all lorazepam presentations.
- Teva did not provide a reason for the shortage.

Estimated Resupply Dates

- Teva has lorazepam 0.5 mg tablets in 100 count bottles, 0.5 mg tablets in 1,000 count bottles, and all 1 mg tablet presentations on back order and the company estimates release dates in mid-February 2021. The 0.5 mg tablets in 500 count bottles are on back order and the company estimates a release date in mid-March 2021. The 2 mg tablets in 500 count and 1,000 count bottles are on back order and the company estimates release dates in late-February 2021.
- Major has lorazepam 0.5 mg in 100 count bottles and 100 count unit-dose packs on back order and the company estimates a release date of mid-February 2021. The 1 mg tablets in 100 count bottles and 100 count unit-dose packs are on back order and the company estimates a release date of mid-February 2021 for the 100 count bottles and late-February 2021 for the 100 count unit-dose packs.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=480>

Polyethylene Glycol 3350 With Electrolytes

February 8, 2021

Reason for the Shortage

- Affordable Pharmaceuticals and Braintree Laboratories have product on allocation due to increased demand.
- Lupin did not provide a reason for the shortage

Estimated Resupply Dates

- Affordable Pharmaceuticals has lemon-lime-flavored polyethylene glycol 3350 with electrolytes (NDC 10572-0302-01) on back order and the company cannot estimate a release date. Their other two presentations are on allocation.
- Braintree Laboratories has Golytely and Nulytely on allocation.
- Lupin has Gavilyte-C and Gavilyte-G on back order and the company estimates release dates in mid-March 2021. Gavilyte-N is on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=688>

Rocuronium Injection

February 9, 2021

Reason for the Shortage

- Athenex did not provide a reason for the shortage. They are no longer marketing the 10 mL vials
- AuroMedics did not provide a reason for the shortage.
- Baxter has rocuronium on shortage due to increased demand.
- Fresenius Kabi has rocuronium on shortage due to increased demand.
- Hikma did not provide a reason for the shortage.
- Mylan Institutional did not provide a reason for the shortage.
- Pfizer has rocuronium on shortage due to increased demand.
- Piramal Critical Care has rocuronium injection available.
- Sagent has rocuronium injection available.
- Sandoz did not provide a reason for the shortage.
- X-Gen has rocuronium injection available.

Estimated Resupply Dates

- AuroMedics has rocuronium 10 mg/mL 5 mL and 10 mL vials on intermittent back order and the company is releasing product as it becomes available.
- Baxter has rocuronium 10 mg/mL 5 mL vials on intermittent back order and the company is releasing product as it becomes available.
- Hikma has rocuronium 10 mg/mL 5 mL and 10 mL vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=290>

Propofol Emulsion Injection

February 9, 2021

Reason for the Shortage

- Dr. Reddy's has propofol on shortage due to increased demand.[1]
- Fresenius Kabi has Diprivan available but may experience intermittent back order due to increased demand. Check wholesaler for inventory.[2]
- Hikma has propofol on shortage due to increased demand.[3]
- Pfizer has propofol on shortage due to increased demand.[4]
- Sagent has propofol on shortage due to increased demand.[5]
- Teva has propofol on shortage due to shipping delays related to COVID-19.[6]

Estimated Resupply Dates

- Dr. Reddy has propofol 20 mL, 50 mL, and 100 mL vials on back order and the company estimates a release date of 3rd quarter 2021 for the 20 mL vials in 25 count and 2nd quarter 2021 for the 50 mL and 100 mL vials. The 20 mL vials in 10 count are on back order and the company cannot estimate a release date.
- Hikma has propofol 20 mL, 50 mL, and 100 mL vial on back order and the company cannot estimate a release date.[3]
- Pfizer has propofol 50 mL vials (NDC 00409-4699-33) on back order and the company estimates a release date of April 2021. All other presentations are available in limited supply.[4]
- Sagent has propofol 20 mL, 50 mL, and 100 mL vials on limited allocation.[5]
- Teva has propofol 100 mL vials on allocation. The 20 mL and 50 mL vials are on back order and the company estimates a release date of February 2021.[6]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=651>

Norepinephrine Bitartrate Injection

February 9, 2021

Reason for the Shortage

- Baxter has norepinephrine injection available.
- Hikma did not provide a reason for the shortage.
- Mylan Institutional did not provide a reason for the shortage.
- Pfizer has Levophed vials on shortage due to increased demand.
- Teva has norepinephrine injection available.

Estimated Resupply Dates

- Hikma has norepinephrine 1 mg/mL 4 mL vials available with short expiration dating (< October 2021).
- Mylan has norepinephrine 1 mg/mL 4 mL vials on back order and the company estimates a release date in mid-February 2021.
- Pfizer has Levophed 1 mg/mL 4 mL vials on back order and the company estimates a release date in April 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=292>

Magnesium Sulfate Injection

February 9, 2021

Reason for the Shortage

- American Regent is not currently marketing magnesium sulfate which has been unavailable since late 2012.
- Fresenius Kabi had magnesium sulfate injection on shortage due to increased demand for the product.
- Pfizer had magnesium sulfate injection on shortage due to manufacturing delays. The 500 mg/mL 20 mL vials were discontinued in August 2020.
- X-Gen discontinued magnesium sulfate in April 2018.
- Exela launched magnesium sulfate vials in May 2018.
- WG Critical Care had magnesium sulfate injection on shortage due to increased demand for the product.

Estimated Resupply Dates

- Exela has 500 mg/mL 10 mL vials available for direct orders only.
- Fresenius Kabi has magnesium sulfate 500 mg/mL 2 mL and 20 mL vials on back order and the company estimates a release date of mid-February 2021 for the 2 mL vials and early-March 2021 for the 20 mL vials. The 40 mg/mL 100 mL premixed bags are on back order and the company estimates a release date of early-March 2021. The 10 mg/mL 100 mL premixed bags are on back order and the company estimates a release date of early- to mid-February 2021.
- Pfizer has magnesium sulfate 500 mg/mL 10 mL syringes on back order and the company estimates a release date of March 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=21>

Hydralazine injection

February 9, 2021

Reason for the Shortage

- Akorn has hydralazine on shortage due to increased demand.
- American Regent is not currently marketing hydralazine injection.
- Fresenius Kabi has hydralazine on back order due to manufacturing delays.
- Mylan has hydralazine injection on shortage due to increased demand.
- X-Gen is not currently manufacturing hydralazine injection.

Estimated Resupply Dates

- Akorn has hydralazine 20 mg/mL 1 mL vials in 25 count on back order and the company cannot estimate a release date.
- Fresenius Kabi has hydralazine 20 mg/mL 1 mL vials on back order and the company estimates a release date of mid-February 2021.
- Mylan Institutional has hydralazine 20 mg/mL 1 mL vials on back order and the company estimates a release date of late-March to early-April 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=431>

Fludarabine Injection

February 9, 2021

Reason for the Shortage

- Areva has fludarabine 25 mg/mL 2 mL vials available.
- Fresenius Kabi had fludarabine on shortage due to manufacturing delays.
- Leucadia has fludarabine lyophilized powder 50 mg vials available.
- Pfizer discontinued fludarabine in August 2020. Their estimated market share was less than 1%.
- Sagent has fludarabine on shortage due to manufacturing delays.
- Teva did not provide a reason for the shortage.

Estimated Resupply Dates

- Teva has fludarabine lyophilized powder 50 mg vials on back order and the company estimates a release date of August 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=622>

Betamethasone Acetate/Betamethasone Sodium Phosphate Suspension for Injection

February 9, 2021

Reason for the Shortage

- American Regent did not provide a reason for the shortage.
- Exela only has short-dated product.
- Merck did not provide a reason for the shortage of Celestone Soluspan.

Estimated Resupply Dates

- American Regent has betamethasone 5 mL vials available in limited supply.
- Exela has betamethasone 5 mL vials on back order and the company estimates a release date of May 2021.
- Merck has Celestone Soluspan 5 mL vials on back order and the company estimates a release date of May 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=684>

Trimethobenzamide Capsules

February 10, 2021

Reason for the Shortage

- All generic trimethobenzamide oral capsules have been discontinued.
- Pfizer did not provide a reason for the shortage of Tigan capsules.
- Trimethobenzamide injection is not affected by this shortage.

Estimated Resupply Dates

- Pfizer has Tigan 300 mg capsules on back order and the company cannot estimate a release date. There are short-dated 300 mg capsules available with an expiration date of September 2021. Drop shipment limits are in place.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=711>

Teprotumumab-trbw Injection

February 10, 2021

Reason for the Shortage

- Horizon Therapeutics has Tepezza on back order because the manufacturing facility is being used to make COVID-19 vaccine. Additional information can be found at <https://www.horizontherapeutics.com/media-center/horizon-resources/statement-on-short-term-tepezza-supply-disruption> or <https://www.hzndocs.com/tepezza-short-term-supply-disruption-FAQ.pdf>.

Estimated Resupply Dates

- Horizon Therapeutics has Tepezza on back order and the company estimates product will be unavailable through first quarter 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=712>

Secobarbital Capsules

February 10, 2021

Reason for the Shortage

- Bausch Health is the sole supplier of secobarbital capsules. The company states that Seconal capsules are on back order due to a short-term stock out.

Estimated Resupply Dates

- Bausch Health has Seconal (secobarbital) 100 mg capsules on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=517>

Methotrexate Injection

February 10, 2021

Reason for the Shortage

- Accord has methotrexate injection on back order due to increased demand.[1]
- Fresenius Kabi has methotrexate injection available.[2]
- Mylan Institutional did not provide a reason for the shortage. They discontinued the 25 mg/mL 10 mL vials in October 2020.[3]
- Pfizer has methotrexate injection available.[4]
- Teva has methotrexate injection available.[5]
- Hikma did not provide a reason for the shortage.[6]

Estimated Resupply Dates

- Mylan Institutional has methotrexate 25 mg/mL 40 mL vials on back order and the company estimates a release date of late-September 2022.[3]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=282>

Iopamidol Injection

February 10, 2021

Reason for the Shortage

- Bracco Diagnostics is the sole supplier of iopamidol and did not provide a reason for the shortage.

Estimated Resupply Dates

- Bracco Diagnostics has Isovue-250 (iopamidol 51%) 50 mL, 150 mL, and 200 mL bottles on back order and the company cannot estimate release dates.
- Bracco Diagnostics has Isovue-300 (iopamidol 61%) in 75 mL, 150 mL, and 200 mL bottles on back order and the company cannot estimate release dates.
- Bracco Diagnostics has Isovue-370 (iopamidol 76%) in 150 mL and 200 mL bottles on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=495>

Heparin Injection

February 10, 2021

Reason for the Shortage

- Fresenius Kabi did not provide a reason for the shortage.
- Hikma did not provide a reason for the shortage.
- Mylan did not provide a reason for the shortage.
- Pfizer has heparin injection on shortage due to increased demand.
- Sagent has heparin injection on shortage due to increased demand and manufacturing delays.

Estimated Resupply Dates

- Fresenius Kabi has short-dated heparin 1,000 unit/mL 10 mL vials available with an expiration date of < 8 months.
- Hikma has heparin 1,000 unit/mL 30 mL vials on back order and the company estimates a release date in third-quarter 2021. The 5,000 unit/mL 10 mL vials are short-dated with an expiration date of February 2021. The 10,000 unit/mL 2 mL vials are short-dated with an expiration date of July 2021.
- Mylan has heparin 20,000 unit/mL 1 mL vials on back order and the company estimates a release date of February 2021. The 1,000 unit/mL 10 mL vials and 5,000 units/mL 10 mL vials are on back order and the company estimates release dates in May 2021. The 10,000 unit/mL 4 mL vials are on back order and the company estimates a release date in April 2021.
- Pfizer has heparin 10,000 unit/mL 0.5 mL Carpuject syringes on back order and the company estimates a release date in March 2021.
- Sagent has heparin 1,000 unit/mL 1 mL vials on limited allocation. The 1,000 unit/mL 2 mL vials and 5,000 unit/mL 10 mL vials are short-dated with an expiration date of August 2021. The 10,000 unit/mL 1 mL vials are on back order and the company estimates a release date in March 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=353>

Dopamine Hydrochloride Injection

February 10, 2021

Reason for the Shortage

- American Regent is not marketing dopamine injection.
- Baxter has dopamine premixed bags available.
- Pfizer states the shortage is due to manufacturing delays. The dopamine 200 mg/250 mL and 400 mg/500 mL premixed bags were discontinued in August 2017.

Estimated Resupply Dates

- Pfizer has dopamine 400 mg/250 mL premixed bags on back order and the company estimates a release date of March 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=246>

Amifostine Injection

February 10, 2021

Reason for the Shortage

- Clinigen is the sole supplier of amifostine injection (Ethyol). Clinigen did not provide a reason for the shortage.

Estimated Resupply Dates

- Clinigen has Ethyol 500 mg vials on back order and the company estimates a release date in late-2021 to early-2022.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=662>

Tramadol Tablets

February 11, 2021

Reason for the Shortage

- Amneal has tramadol tablets available.
- Major discontinued tramadol tablets.
- Mylan has tramadol tablets available.
- Sun Pharma has tramadol tablets available.
- Teva did not provide a reason for the shortage.
- Virtus has tramadol tablets on shortage due to increased demand.
- Zydus discontinued tramadol tablets.

Estimated Resupply Dates

- Teva has tramadol 50 mg tablets in 500 count bottles on intermittent back order and the company is releasing supplies as they become available.
- Virtus has tramadol 50 mg tablets in 100 and 500 count bottles on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=628>

Epinephrine Auto-Injectors

February 11, 2021

Reason for the Shortage

- Amneal did not provide a reason for the shortage.
- Mylan has epinephrine auto-injectors available.
- Sandoz discontinued Symjepi in October 2020.
- Teva did not provide a reason for the shortage.

Estimated Resupply Dates

- Amneal has epinephrine 0.15 mg/0.15 mL auto-injectors on hold and the company cannot estimate a release date. The 0.3 mg/0.3 mL auto-injectors are on allocation.

- Teva has epinephrine 0.15 mg/0.15 mL and 0.3 mg/0.3 mL auto-injectors on intermittent back order and the company is releasing supplies as they become available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=420>

Cefazolin Injection

February 11, 2021

Reason for the Shortage

- Apotex has cefazolin injection available.
- Baxter has cefazolin on shortage due to increased demand.
- BBraun has cefazolin on shortage due to manufacturing delays.
- Fresenius Kabi has cefazolin injection available. They are not manufacturing the 20 gram vials at this time to focus on the other sizes.
- Hikma has cefazolin injection available.
- Pfizer states the reason for the shortage was increased demand. Pfizer is only currently marketing the 1 gram ADD-Vantage vials.
- Sagent has cefazolin injection available.
- Samson Medical Technologies has cefazolin injection available.
- Sandoz has cefazolin injection available.
- WG Critical Care has cefazolin injection available.

Estimated Resupply Dates

- Baxter has cefazolin 2 gram/100 mL premixed bags on allocation.
- BBraun has 1 gram/50 mL and 2 gram/50 mL premixed bags on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=432>

Valproate Sodium Injection

February 16, 2021

Reason for the Shortage

- Hikma did not provide a reason for the shortage.
- Fresenius Kabi has valproate sodium on shortage due to increased demand.

Estimated Resupply Dates

- Fresenius Kabi has valproate sodium 100 mg/mL 5 mL vials on back order and the company estimates a release date of mid-April 2021.
- Hikma has valproate sodium 100 mg/mL 5 mL vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=657>

Thiamine Injection

February 16, 2021

Reason for the Shortage

- Fresenius Kabi did not provide a reason for the shortage.
- Mylan Institutional did not provide a reason for the shortage.
- Sagent has thiamine injection on shortage due to manufacturing delays.

Estimated Resupply Dates

- Fresenius Kabi has thiamine 100 mg/mL 2 mL vials on back order and the company estimates a release date of late-February 2021.
- Mylan Institutional has thiamine 100 mg/mL 2 mL vials on back order and the company estimates a release date of late-June to early-July 2021.
- Sagent has thiamine 100 mg/mL 2 mL vials on limited allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=502>

Posaconazole Injection

February 16, 2021

Reason for the Shortage

- Merck did not provide a reason for the shortage. They are the sole suppliers of posaconazole injection.

Estimated Resupply Dates

- Merck has Noxafil 300 mg vials available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=706>

Phenytoin Sodium Injection

February 16, 2021

Reason for the Shortage

- Hikma did not provide a reason for the shortage.

Estimated Resupply Dates

- Hikma has phenytoin sodium 50 mg/mL 5 mL vials on back order and the company estimates a release date of late-February 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=678>

Octreotide Injection

February 16, 2021

Reason for the Shortage

- Fresenius Kabi has octreotide on shortage due to manufacturing delays.
- Hikma did not provide a reason for the shortage.
- Mylan Institutional did not provide a reason for the shortage.
- Sagent has octreotide on shortage due to manufacturing delay.
- Sun Pharma has Bynfezia Pen available.
- Teva has octreotide on shortage due to increased demand.
- Novartis has Sandostatin available. The 200 mcg/mL 5 mL vials were discontinued in early-2018.

Estimated Resupply Dates

- Fresenius Kabi has octreotide 100 mcg/mL 1 mL vials on back order and the company estimates a release date of mid-February 2021. The 200 mcg/mL 5 mL vials are on back order and the company estimates a release date of mid-March 2021.
- Hikma has octreotide 50 mcg/mL 1 mL vials and 100 mcg/mL 1 mL vials are on back order and the company estimates a release date of late-February 2021. The 500 mcg/mL 1 mL vials are on allocation.

The 200 mcg/mL 5 mL vials are on back order and the company cannot estimate a release date. There are short-date 1,000 mcg/mL 5 mL vials available with an expiration date of June 2021.

- Mylan Institutional has octreotide 500 mcg/mL 1 mL syringes on back order and the company estimates a release date of late-March 2021.
- Sagent has octreotide 50 mcg/mL 1 mL vials, 100 mcg/mL 1 mL vials, and 500 mcg/mL 1 mL vials on back order and the company estimates a release date of March 2021. The 200 mcg/mL 5 mL vials and 1,000 mcg/mL 5 mL vials are on back order and the company estimates a release date of August 2021.
- Teva has octreotide 500 mcg/mL 1 mL vials on back order and the company estimates a release date of April 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=229>

Calcium Gluconate Injection

February 16, 2021

Reason for the Shortage

- Fresenius Kabi has calcium gluconate on shortage due to increased demand.
- WG Critical Care has calcium gluconate premixes available.

Estimated Resupply Dates

- Fresenius Kabi has calcium gluconate 100 mg/mL 50 mL and 100 mL vials on back order and the company estimates a release date of early-March 2021 for the 50 mL vials and early- to mid-March 2021 for the 100 mL vials

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=714>

Azacitidine Injection

February 16, 2021

Reason for the Shortage

- Accord has azacitidine on back order due to a shortage of the raw ingredient.
- Armas has azacitidine on shortage due to increased demand.
- Dr. Reddy's has azacitidine on shortage due to increased demand.
- Fresenius Kabi has azacitidine on shortage due to increased demand.
- Hikma has azacitidine on shortage due to increased demand.
- Mylan Institutional did not provide a reason for the shortage.
- Sandoz has azacitidine on shortage due to increased demand.
- Wockhardt did not provide a reason for the shortage.
- Celgene (now part of Bristol-Myers Squibb) has Vidaza on shortage due to increased demand.

Estimated Resupply Dates

- Accord has azacitidine 100 mg vials on back order and the company cannot estimate a release date.
- Armas has azacitidine 100 mg vials on back order and the company cannot estimate a release date.
- Celgene has Vidaza 100 mg vials on allocation.
- Cipla has azacitidine 100 mg vials on back order and the company cannot estimate a release date.
- Dr. Reddy's has azacitidine 100 mg vials on intermittent back order and the company is releasing product as it becomes available.

- Fresenius Kabi has azacitidine 100 mg vials on back order and the company estimates a release date of early-April 2021.
 - Hikma has azacitidine 100 mg vials on allocation.
 - Mylan Institutional has azacitidine 100 mg vials on back order and the company estimates a release date of late-March to early-April 2021.
 - Wockhardt has azacitidine 100 mg vials on back order and the company cannot estimate a release date.
- <https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=693>

Alprostadil Urethral Suppositories

February 16, 2021

Reason for the Shortage

- Mylan did not provide a reason for the shortage.

Estimated Resupply Dates

- Mylan has Muse 125 mcg and 250 mcg suppositories on back order and the company estimates a release date of mid-February 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=605>

Vecuronium Bromide Injection

February 17, 2021

Reason for the Shortage

- AuroMedics did not provide a reason for the shortage.[1]
- Fresenius Kabi has vecuronium on shortage due to increased demand.[2]
- Hikma did not provide a reason for the shortage.[3]
- Mylan Institutional did not provide a reason for the shortage.[4]
- Pfizer has vecuronium on shortage due to increased demand.[5]
- Sun Pharma has vecuronium on shortage due to increased demand.[6]
- Teva has vecuronium available.

Estimated Resupply Dates

- AuroMedics has vecuronium 10 mg and 20 mg vials on back order and the company cannot estimate a release date.[1]
- Hikma has vecuronium 10 mg vials on allocation. The 20 mg vials are on back order and the company estimates a release date of late-March 2021.[3]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=167>

Testosterone Enanthate Intramuscular Injection

February 17, 2021

Reason for the Shortage

- Hikma has testosterone enanthate available.
- Teva did not provide a reason for the shortage.

Estimated Resupply Dates

- Teva has testosterone enanthate 200 mg/mL 5 mL vials temporarily unavailable with no estimated release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=498>

Testosterone Cypionate Injection

February 17, 2021

Reason for the Shortage

- Cipla has testosterone cypionate available.
- Hikma and Perrigo have testosterone cypionate available.
- Pfizer has testosterone cypionate and Depo-Testosterone on shortage due to increased demand.
- Sun Pharma has testosterone cypionate available.

Estimated Resupply Dates

- Pfizer has all generic presentations and all presentations of Depo-Testosterone available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=592>

Rifampin Injection

February 17, 2021

Reason for the Shortage

- Fresenius Kabi stated the reason for the shortage was a short-term manufacturing delay.
- Mylan did not provide a reason for the shortage.
- Sanofi-Aventis did not provide a reason for the shortage.

Estimated Resupply Dates

- Fresenius Kabi has rifampin 600 mg vials on back order and the company estimates a release date of early- to mid-March 2021.
- Mylan Institutional has rifampin 600 mg vials on back order and the company estimates a release date of late-March 2021.
- Sanofi-Aventis has Rifadin IV 600 mg vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=713>

Pantoprazole Injection

February 17, 2021

Reason for the Shortage

- AuroMedics had pantoprazole injection on shortage due to increased demand.
- Hikma did not provide a reason for the shortage.
- Pfizer had Protonix injection on shortage due to manufacturing delays.

Estimated Resupply Dates

- AuroMedics has pantoprazole 40 mg vials on intermittent back order and the company is releasing product as it becomes available.
- Hikma has pantoprazole 40 mg vials on allocation.

- Pfizer has Protonix 40 mg vials in 10 count and 25 count available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=550>

Ketorolac Injection

February 17, 2021

Reason for the Shortage

- Alvogen did not provide a reason for the shortage.[1]
- Amphastar has discontinued ketorolac injection.[2]
- Athenex did not provide reason for the shortage.[3]
- Baxter has ketorolac on shortage due to increased demand.[4]
- BD RX is now part of Fresenius Kabi.[5]
- Fresenius Kabi has most ketorolac presentations available.[7]
- Fosun Pharma has ketorolac available.[6]
- Pfizer has ketorolac injection on back order due to manufacturing delays.[8]
- Sagent states the reason for the shortage is manufacturing delay.[9]
- Hikma is not actively manufacturing ketorolac at this time.[10]
- Ben Venue closed its plant in Bedford, Ohio in July 2014.[11]
- Virtus discontinued ketorolac in March 2019.[12]
- FDA imposed an import ban in mid-2013 on several Wockhardt products including ketorolac.[13]
- Sprix Nasal Spray is not affected by this shortage.[14]

Estimated Resupply Dates

- Fresenius Kabi has ketorolac 15 mg/mL 1 mL vials on back order and the company estimates a release date of early- to mid-March 2021. The 30 mg/mL 1 mL vials are on back order and the company estimates a release date of early-March 2021. The 30 mg/mL 2 mL vials for intramuscular use are on back order and the company estimates a release date of late-March 2021.[7]
- Pfizer has ketorolac 30 mg/mL 1 mL Carpuject syringes on back order and the company estimates a release date of February 2021. The 30 mg/mL 2 mL Carpuject syringes for intramuscular injection are on back order and the company estimates a release date of February 2021. The 15 mg/mL 1 ml vials are available in limited supply.[8]
- Sagent has ketorolac 15 mg/mL 1 mL vials, 30 mg/mL 1 mL vials, and 30 mg/mL 2 mL vials for intramuscular injection on back order and the company cannot estimate a release date.[9]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=113>

Ketamine Injection

February 17, 2021

Reason for the Shortage

- Hikma did not provide a reason for the shortage.
- Mylan Institutional discontinued ketamine in December 2020.
- Par has Ketalar available.
- Pfizer has ketamine on shortage due to manufacturing delays.

Estimated Resupply Dates

- Hikma has ketamine 50 mg/mL 10 mL vials on back order and the company estimates a release date of early-April 2021.
- Pfizer has ketamine 50 mg/mL 10 mL vials on back order and the company estimates a release date of June 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=391>

Histrelin Implant

February 17, 2021

Reason for the Shortage

- Hikma is not actively manufacturing ketorolac at this time.[10]
- Ben Venue closed its plant in Bedford, Ohio in July 2014.[11]
- Virtus discontinued ketorolac in March 2019.[12]
- FDA imposed an import ban in mid-2013 on several Wockhardt products including ketorolac.[13]
- Sprix Nasal Spray is not affected by this shortage.[14]

Estimated Resupply Dates

- Fresenius Kabi has ketorolac 15 mg/mL 1 mL vials on back order and the company estimates a release date of early- to mid-March 2021. The 30 mg/mL 1 mL vials are on back order and the company estimates a release date of early-March 2021. The 30 mg/mL 2 mL vials for intramuscular use are on back order and the company estimates a release date of late-March 2021.[7]
- Pfizer has ketorolac 30 mg/mL 1 mL Carpuject syringes on back order and the company estimates a release date of February 2021. The 30 mg/mL 2 mL Carpuject syringes for intramuscular injection are on back order and the company estimates a release date of February 2021. The 15 mg/mL 1 ml vials are available in limited supply.[8]
- Sagent has ketorolac 15 mg/mL 1 mL vials, 30 mg/mL 1 mL vials, and 30 mg/mL 2 mL vials for intramuscular injection on back order and the company cannot estimate a release date.[9]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=113>

Ketamine Injection

February 17, 2021

Reason for the Shortage

- Hikma did not provide a reason for the shortage.
- Mylan Institutional discontinued ketamine in December 2020.
- Par has Ketalar available.
- Pfizer has ketamine on shortage due to manufacturing delays.

Estimated Resupply Dates

- Hikma has ketamine 50 mg/mL 10 mL vials on back order and the company estimates a release date of early-April 2021.
- Pfizer has ketamine 50 mg/mL 10 mL vials on back order and the company estimates a release date of June 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=391>

Histrelin Implant

February 17, 2021

Reason for the Shortage

- Endo has Vantas on shortage due to a manufacturer investigation that paused production.

Estimated Resupply Dates

- Endo has Vantas on back order and the company is unable to provide an estimated release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=716>

Haloperidol Lactate Injection

February 17, 2021

Reason for the Shortage

- Fresenius Kabi has haloperidol lactate injection on shortage due to increased demand.
- Hikma did not provide a reason for the shortage.
- Janssen discontinued Haldol injection in November 2020.
- Mylan Institutional did not provide a reason for the shortage.
- Patriot Pharmaceuticals discontinued haloperidol lactate injection in November 2020.
- Sagent has haloperidol lactate injection on shortage due to increased demand.

Estimated Resupply Dates

- Fresenius Kabi has haloperidol lactate injection 5 mg/mL vials on back order and the company estimates a release date of early-March 2021.
- Hikma has haloperidol lactate injection 5 mg/mL vials on back order and the company estimates a release date of 4th quarter 2021.
- Mylan Institutional has haloperidol lactate injection 5 mg/mL vials on back order and the company estimates a release date of early-March 2021.
- Sagent has haloperidol lactate 5 mg/mL 1 mL vials on back order and the company estimates a release date of April 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=698>

Lidocaine With Epinephrine Injection

February 18, 2021

Reason for the shortage

- Fresenius Kabi has Xylocaine with epinephrine presentations on shortage due to increased demand for the product and manufacturing delays.
- Pfizer has lidocaine with epinephrine presentations on shortage due to manufacturing delays.

Estimated Resupply Dates

- Fresenius Kabi has 0.5% Xylocaine (1:200,000) 50 mL vials on back order and the company estimates a release date of late-February 2021. The 1% Xylocaine (1:200,000) 10 mL and 20 mL vials are on back order and the company estimates a release date of mid-February 2021. The 1% Xylocaine (1:200,000) 50 mL vials are on back order and the company estimates a release date of late-February 2021. The 1% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials are on back order and the company estimates a

release date of early- to mid-March 2021. The 1% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials in sterile packs are on back order and the company cannot estimate a release date. The 1.5% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials are on back order and the company estimates a release date of mid-April 2021. The 1.5% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials in sterile packs are on back order and the company cannot estimate a release date. The 2% Xylocaine with epinephrine (1:200,000) 20 mL vials are on back order and the company estimates a release date of mid-April 2021. The 2% Xylocaine-MPF (1:200,000) 10 mL vials are on back order and the company estimates a release date of early- to mid-March 2021. The 2% Xylocaine-MPF (1:200,000) 20 mL vials are on back order and the company cannot estimate a release date. The 2% Xylocaine-MPF with epinephrine (1:200,000) 20 mL vials in sterile packs are on back order and the company cannot estimate a release date. Check wholesalers for inventory.

- Pfizer has 0.5% lidocaine (1:200,000) 50 mL vials on back order and the company estimates a release date of February 2021. The 1% lidocaine (1:100,000) 20 mL and 50 mL vials are on back order and the company estimates a release date of February 2021. The 1% lidocaine (1:100,000) 30 mL vials are available in limited supply. The 2% lidocaine (1:100,000) 20 mL and 50 mL vials are on back order and the company estimates a release date of February 2021 for the 20 mL vials and March 2021 for the 50 mL vials.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=261>

Bupivacaine with Epinephrine Injection

February 18, 2021

Reason for the Shortage

- Fresenius Kabi has bupivacaine and epinephrine on shortage due to increased demand and manufacturing delays.
- Pfizer has bupivacaine with epinephrine on shortage due to manufacturing delays.

Estimated Resupply Dates

- Fresenius Kabi has 0.25% Sensorcaine-MPF with epinephrine 10 mL and 30 mL vials on back order and the company estimates a release date of early-March 2021. The 0.25% Sensorcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of early-March 2021. The 0.5% Sensorcaine-MPF with epinephrine 10 mL and 30 mL vials are on back order and the company estimates a release date of early-March 2021 for the 10 mL vials and late-February 2021 for the 30 mL vials. The 0.5% Sensorcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of mid-February 2021. The 0.5% Sensorcaine-MPF with epinephrine 30 mL sterile packs are on back order and the company cannot estimate a release date. The 0.75% Sensorcaine-MPF with epinephrine 30 mL vials are on back order and the company estimates a release date of mid-April 2021.
- Pfizer has 0.25% bupivacaine with epinephrine 10 mL preservative-free vials on back order and the company estimates a release date of July 2022. The 0.25% bupivacaine with epinephrine 30 mL preservative-free vials are on back order and the company estimates a release date of July 2022. The 0.25% bupivacaine with epinephrine 50 mL vials are on back order and the company estimates a release

date of July 2022. The 0.5% bupivacaine with epinephrine 10 mL preservative-free vials are on back order and the company estimates a release date of July 2022. The 0.5% bupivacaine with epinephrine 30 mL preservative-free vials are on back order and the company estimates a release date of July 2022. The 0.5% bupivacaine with epinephrine 50 mL vials are on back order and the company estimates a release date of July 2022.

- Pfizer has 0.25% Marcaine with epinephrine 10 mL preservative-free vials on back order and the company estimates a release date of June 2021. The 0.25% Marcaine with epinephrine 30 mL preservative-free vials are on back order and the company estimates a release date of June 2021. The 0.25% Marcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of June 2021. The 0.5% Marcaine with epinephrine 10 mL preservative-free vials are on back order and the company estimates a release date of June 2021. The 0.5% Marcaine with epinephrine 30 mL preservative-free vials are on back order and the company estimates a release date of June 2021. The 0.5% Marcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of June 2021.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=261>

*Please refer to ASHP website for more information at: <https://www.ashp.org/Drug-Shortages/Current-Shortages>